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ABSTRACT
Here, the BBB-crossing ability of a Trojan horse peptide conjugated to a short
therapeutic peptide was evaluated, with the aim to halt the progression of TBI-associated
neuronal damage in a mouse experimental model of TBI. An associated study was also
conducted to develop a new biosensor to probe hydrogen peroxide – a biomarker of
chronic inflammation in the brain. The long-term goal of this study was to assess the
regenerative or neuroprotective effect of this potential therapeutic peptide on neural
disease pathology, thus expanding the known library of BBB-crossing peptides, and
developing new tools for the study of inflammation, such as the biosensor used in this
project.
First, the receptor-targeting peptides were designed and synthesized, followed by
studying their uptake into different cell types of the BBB in vitro and quantifying the
degree of the uptake. Subsequently, a therapeutic anti-inflammatory peptide was
conjugated to the main peptide of interest, i.e., the Trojan horse peptide, and then its
uptake was validated in vivo in mouse models of TBI. The focus was on executing this
uptake via a non-invasive mode of administration i.e., intranasally, over a short, 7-day
timeframe. The ultimate goal of this study was to test if this peptide conjugate could also
cross the BBB and localize in the brain just as was demonstrated when studied by itself.
Through histological analysis of TBI-injured, peptide-treated mouse brains, it was
determined that the peptide localizes in the olfactory bulbs in the brain, regardless of
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whether the brain was injured. No evidence was found for localization in other brain
regions in this preliminary study.
A new biosensor was developed in a collaborative project. It was shown to
accurately sense acute oxidative stress in vitro through the detection of hydrogen
peroxide in cultured mouse macrophage cells. This probe shows great promise in
detecting hydrogen peroxide in an extracellular assay of inflammation in the future.
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INTRODUCTION
1.1

Research Need

Despite tremendous advancement in modern medicine and technology,
neurodegenerative diseases affecting the central nervous system (CNS) such as
Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS) continue to plague the
human population. The blood–brain barrier (BBB) has a significant contribution to the
homeostasis and protection of the CNS. However, it also limits the crossing of
therapeutics and thereby complicates the treatment of CNS diseases. Macromolecules,
such as proteins and nucleic acids, are prevented from paracellular and transcellular
transport by specialized CNS barriers such as brain capillary endothelial cells of the
BBB. This formidable challenge is one key reason why these disorders remain largely
untreated, despite the ready availability of candidate drugs that could effectively treat
them. There is an urgent need to develop new therapeutics or modify existing ones to
cross the BBB to access cellular and molecular targets inside the brain.
In addition to neurodegeneration, accidental conditions such as injury to the brain
can cause acute or gradual pathophysiological changes in the morphology and damage to
brain cells, especially neurons, over time. The current state of treatment in such cases,
like traumatic brain injury (TBI), is lacking in efficacy, especially taking into
consideration the dearth of pharmaceuticals to treat them. There is an unmet need for
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pharmaceuticals that not only provide adequate palliative care, but also have long-term
neuroprotective benefits coupled with recovery of the injured tissues and an overall
reduction in the potential damage caused.
1.2

Current State of Research

Over the last decade, interest has increased in in neuropharmaceuticals to treat
CNS disorders and TBI, as reviewed earlier [1]–[3]. An extremely limited number of
drugs (about 5% of the drugs in the Comprehensive Medicinal Chemistry database) [4]
treat CNS disorders, but they relate exclusively to three conditions: depression,
schizophrenia, and insomnia [5]. Rationally designed peptides with certain functionalities
can offer several advantages over chemical pharmaceuticals such as higher in vivo
efficacy and reduction of potential side-effects. These advantages also include their high
specificity which can be attributed to their chemical and biological diversity. In addition,
small peptides fall below the immunogenic threshold. They generally do not induce a
strong immune response and are usually non-toxic. The relative ease of modification to
optimize their pharmacokinetic properties is another advantage. The utilization of
peptides and peptidomimetics can also rehabilitate protein or peptide fusion drugs that are
currently limited in their commercial application due to poor half-life and low
bioavailability.
Peptides are considered the new generation of biologically active tools because
they are key regulators in cellular and intercellular physiological responses, which
possess enormous potential for the treatment of various diseases. Consequently, the
pharmaceutical industry has made great strides in the development of peptide
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therapeutics, with over 60 FDA-approved therapeutic peptides in the US, Europe and
Japan markets and more than 150 are currently in clinical studies [6]. The utilization of
peptides as therapeutics has evolved over time and continues to evolve with changes in
drug development and treatment paradigms. Despite their clinical potential, native
peptides have seen limited use due to their poor bioavailability and low stability in
physiological conditions. They are also unlikely to be membrane-permeable and they
require a vector system to deliver them inside cells.
The most promising method to transport drugs across the BBB is the ‘Trojan
horse’. This method involves chemically conjugating a therapeutic molecule with a
known molecule that can cross the BBB. These ’Trojan horse’ peptides are referred to as
targeting peptides because they directly target a therapeutic to the CNS. Many of these
molecules transport therapeutics across the BBB using receptor-mediated transcytosis
(RMT) [4]. It is crucial that receptors useful for this purpose be expressed on the luminal
membrane of the brain capillary endothelium, to be appropriate targets for these Trojan
horse peptides. While this method has proven effective in transporting therapeutics across
the barrier, many of the therapeutics that employ this method alter the endocytic pathway
such that a substantial portion of the therapeutic molecules are shuttled to lysosomes for
degradation [7]. However, the argument remains that disease outcomes might be changed
if even small concentrations of a therapeutic cross the BBB.
Small cationic peptides, in particular, have been used in a Trojan horse-like
approach to remediate brain disorders. A SynB1 protegrin derivative was used to deliver
benzylpenicillin across the BBB [8] and Tat-NR2B9c and pTat-PDZ1-2 have been used
to treat ischemic brain damage [9]–[11]. Efficient delivery of nanoparticles and
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macromolecular drugs into the brain often depends upon BBB-permeable carriers. The
BBB-penetrating ability of these carriers can be hindered by the blood clearance through
the immune system and, degradation by ambient enzyme, preventing adequate dosage
from reaching the brain parenchyma, and being detectable by fluorescent microscopy.
Therefore, peptides are a promising strategy for BBB penetration and delivery of
therapeutics as they can be readily modified to overcome these obstacles and suit
different drug delivery strategies.
1.3

Research Hypothesis and Specific Aims

Understanding the cargo-carrying capacity, BBB-penetrating capability of peptide
vectors and their biodistribution in the brain are fundamental to their transition from the
in vitro to the in vivo setting. Alternatives to current BBB-penetrating vectors or
therapeutics need to be identified and studied to increase the library of potential
candidates for BBB delivery of pharmaceuticals to treat diseases of the CNS and
damaged cells in injured brains.
The primary objective of this research is to establish the utility of the peptide L57
as a drug delivery vector for a conjugated therapeutic peptide anti-inflammatory peptide
(AIP). The hypothesis to be investigated is that the newly discovered peptide L57 can be
used as a vector to efficiently deliver therapeutic entities across the blood-brain barrier to
treat diseases of the central nervous system or injured brains using a non-invasive route
of administration.
To test this hypothesis, the following specific aims were investigated: 1) To test
the ability of L57 to enter endothelial cells in vitro via LRP1 RMT. 2) To test the ability
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of L57-AIP peptide conjugate to cross the BBB and study its therapeutic effect on injured
mouse brains in a TBI model of injury, through a non-invasive route of administration.
This dissertation incorporates work from two publications by the author. Chapter
2 reviews traumatic brain injury concepts in the context of this study, the BBB and
current treatment paradigms and available RMT-mediated BBB shuttle peptides. In
Chapter 3, the rational design, synthesis, and characterization of the peptides used in this
study are elaborated, with a focus on designing the peptides to ensure optimal intranasal
(IN) delivery, as a non-invasive route of administration is one of the highlights of this
research. Chapter 4 was previously published [12] in the October 2020 issue of The
Journal of Pharmaceutical Sciences and explains the in vitro uptake and cytotoxicity
studies of the L57, Angiopep-7 and R8 peptides in different BBB cell cultures.
Experimental mouse models of TBI are studied in Chapter 5, validating the BBBcrossing ability and brain bio-distribution of the L57 peptide and its conjugate, coupled
with the use of neurobehavioral testing to study mouse behavior in peptide-treated vs,
untreated mice. An interdisciplinary approach to diagnose inflammation is adopted and
explained in the penultimate chapter, Chapter 6 – the proof-of-concept study of an
electrochemical sensing probe for the in vitro detection of hydrogen peroxide, a reactive
oxygen species implicated in inflammation. Chapter 6 was previously published [13] in a
Special Issue of the Sensors journal: Electrochemical Biosensors for Cell-Secreted and
Cell-Surface-Expressed Biomarkers Detection.

BACKGROUND
2.1

Traumatic Brain Injury

According to the CDC, traumatic brain injury (TBI) is a leading cause of death in
the USA, disproportionately affecting people prone to being in violent situations such as
military combat and in correctional institutions [15]. Being a country with the highest per
capita firearm ownership in the world, death by firearm suicide is prevalent. In 2017,
death by firearm suicide was the major cause of all TBI-related deaths, with the second
and third being unintentional falls and motor vehicle accidents [14].
TBI can be defined as “an acquired brain injury initiated by mechanical forces
applied almost instantaneously” [16]. This definition excludes TBIs such as crush
injuries, hemorrhages, or intracranial tumors. TBI occurs with the transient application
(~20 msec) of a mechanical force (impact or acceleration-deceleration) to the brain that
damages cellular membranes, axons, and the vasculature, leaving histopathological
hallmarks of TBI across multiple brain regions.” [16]. It is classified into three types:
mild, moderate, and severe TBI, depending on the severity of the injury. Mild cases
comprise approximately 75% of all TBI cases according to a 2003 CDC report [15], the
rest being moderate to severe cases. The difficulty of diagnosis of the type of TBI makes
this a “silent epidemic” and wide-varying states in associated pathophysiology is what
makes TBI complicated to treat.
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The dismantling of neural circuitry in the brain following the progression of
pathological processes consequently leads to posttraumatic morbidity, manifesting in
neuropsychiatric sequelae- a widely prevalent one being depression [17], as well as
problems associated with information processing, memory, cognition, communication
[18] and somatic symptoms such as headaches and dizziness. Endogenous repair of
neural circuitry in the brain is compounded by haphazard repair mechanisms due to the
lack of patterned signals [19]. The diagnosis of TBI in neurotrauma patients, and their
subsequent treatment and rehabilitation has involved multidisciplinary efforts, with
translational research in neurotrauma being at the forefront of fortifying TBI patient care
and improving health outcomes.
2.1.1

Primary and Secondary Damage
The primary traumatic insult consists of the initial mechanical injury that may or

may not involve penetration of the skull. If the skull is penetrated, the injury is referred to
as an open-head injury. Closed-head injury, on the other hand, does not involve breaking
the skull; however, the brain tissue is injured, and symptoms may be either obvious
immediately or present clinically later, depending on the intensity of the primary
mechanical force.
Primary damage is mostly limited to direct head trauma, comprising mechanical
forces such as acceleration and deceleration linear forces, rotational forces [20], shear,
displacement, stretching and tearing which can directly damage glial tissues, vasculature,
and neural cells [21], [22]. The impacted brain may also suffer from subdural hematoma
and cerebral ischemia [23]. In the case of concussions, there may be loss of
consciousness, and in more severe cases, lacerations that directly impact brain
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parenchyma resulting in the disruption of neural, chemical, and electrical pathways in the
brain.
The primary event subsequently triggers the secondary injury cascade which is
mostly non-linear and progresses over a prolonged time [16]. This cascade includes
molecular events that take place over a short time frame (acute), such as axolemma
membrane permeability [24] and generation of reactive oxygen species (ROS) [25], or
processes that have progressed over an extended time (chronic), as in the case of
neurodegeneration [23].
2.1.2

Diffuse Axonal Injury
Diffuse axonal injury (DAI) is the main pathological hallmark of human TBI,

caused by both the primary and secondary mechanisms of TBI [26], [27]. It is
characterized by diffuse white matter degeneration in the cerebrum, brain stem, corpus
callosum and even the cerebellum [26]. In all these regions it is stereotypically
heterogeneous with multifocal as well as diffuse components [20], [26]. The
susceptibility of axons in white matter to injury can be attributed to their viscoelastic
nature, anisotropy in the brain, linear arrangement of the filamentous neuronal
cytoskeleton, presence/absence of myelination and large axolemma-to-axoplasm surface
area [28]. Except in severe cases, i.e., the minority of TBI cases, primary axotomy
(transection of the axon) is rare, in contrast to secondary axotomy. The latter is a
calcium-mediated neuropathological cascade resulting in the disruption of neural
networks that coordinate normal, healthy behavior. Povlishock et al. [29] discovered the
non-uniform timeline of individual neurons entering the pathological cascade in the postacute and chronic phases of brain injury, with evidence of axotomy seen commencing at

9
3-4 hours after injury in smaller animals like rodents and at 12 hours in humans [30],
[31].
This axonal damage can be identified by pathological features at several states of
degeneration - undulations, varicosities, and bulbs, subsequently leading to secondary
axotomy and Wallerian degeneration (active degeneration of the injured distal portion of
an axon) [28]. Dynamic stretch injury at 50-75% strain precipitates a loss of elasticity and
cytoskeletal mechanical damage due to the breaking of microtubules disallowing the reorientation of the neurons to their pre-traumatic state [32]. The resulting temporary
misalignment causes an “axonal undulation” [32], [33].
Microtubule damage also causes accumulation of transported protein cargoes at
periodic points along the length of the axons [32]. This specific morphology, termed
“axonal varicosity” has a bead-like or “varicose” appearance and was discovered in vitro
by Rand and Courville in 1946 [34]. It is characterized by interruption of axonal
transport. They can be visualized by the immunocytochemical labeling, using antibodies
against the beta-amyloid precursor protein (β-APP) in degenerating neurons [35].
After disconnection of the axon within at least 12 hours after the primary insult in
humans [30], the two parts of the disconnected axon, proximal (closer to the cell body)
and distal bulbs (fragment of the disconnected axon), retract away from the axotomic
locus, with the distal bulb undergoing Wallerian degeneration [36].The APP in these
“axonal bulbs” can also be stained to detect and identify them.
As axonal pathology is heterogeneous and the progress of the pathological
cascade not extensively investigated beyond 2-3 weeks after experimental injury [37], the
experimental characterization of chronic phase of TBI has not yet been explored in depth.
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2.1.3

Inflammation in Traumatic Brain Injury
The inflammatory response to TBI is mediated by pro- and anti-inflammatory

cytokines, chemokines, and glial cell activation in the CNS [38], following an excitatory
neurotransmitter (e.g., glutamate) burst [39]. The sentient immune cells of the CNS- the
microglia and astroglia, and neurons produce cytokines in their resting state. In humans,
cytokines such as IL-6 (pro), IL-8 (pro) and IL-10 (anti) [40]; and in rodents, IL-1 (pro),
IL-6 (pro), TNF (pro) and IL-4 (anti) [41] are normally present in the CNS.
Cytokines produced by the microglia are involved in homeostasis- guiding
neuronal growth and repair, but also in progressing the pathology of CNS trauma.
However, in response to the glutamate burst, the astrocytes and neurons rapidly excrete
proinflammatory cytokines (TNF-α, IL-6, IL-12) and chemokines such as CXCL1 [42] as
well as ROS [23]. The excess extracellular glutamate availability in turn causes terminal
membrane depolarization in neurons and astrocytes which over-stimulates the ionotropic
and metabotropic glutamate receptors. This breakdown of the ion channels results in
Ca2+, Na+, and K+ fluxes which ultimately culminate in the breakdown of the BBB [23].
The role of the BBB in TBI will be discussed in the next sub-section.
Both pro- and anti-inflammatory cytokines and chemokines are present in the
CNS under resting and pathological conditions. They are thought to balance the immune
response in terms of restorative and destructive effects [43]. The inflammation cascade in
relation to the BBB can be summarized in Figure 2-1. In terms of secondary axotomy,
axotomy-induced expression of cytokines is necessary for activating axon regeneration
[44]. This requirement is an important observation to be considered while exploring TBI
therapies.
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Figure 2-1: TBI-induced injury cascade and its effects of TBI on systemic immunity.
The disrupted BBB is leaky, and it allows the immune cell infiltration into the brain.
Neuronal death is caused by the onset of TBI, and eventually neuronal recovery is aided
by anti-inflammatory cytokines. From Das et al., 2012 [23].
2.1.4

Traumatic Brain Injury and the Blood-Brain Barrier
A traumatic insult to the brain usually results in a transient opening of the BBB,

thereby activating the coagulation cascade [45]. This BBB breakdown does not take place
in isolation. Rather, it includes the entire neurovascular unit (NVU) that the BBB is part
of. This NVU comprises the vascular or endothelial cells, perivascular glial cells, neurons
and the extracellular matrix, all functioning as an integrated unit with complex,
pathophysiological responses to trauma [37]. The endothelial cells are connected laterally
by tight junction protein complexes which contribute to the integrity of the BBB. Various
barriers prevent entry of unwanted molecules into the brain and are crucial to BBB
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integrity: 1) physical barriers: prevent paracellular transport into the brain, 2) transport
barriers: the transport proteins, cell-surface receptors for endocytosis and ATP-binding
proteins, all of which regulate transport- entry of nutrients and efflux of toxins, 3)
metabolic barrier: metabolic enzymes such as P450 [46]. TBI disrupts the NVU,
including the tight junctions. Gadolinium-enhanced magnetic resonance imaging and
Evans Blue can be used to detect the consequent BBB leakage as early 25 minutes postinjury and up to 5 weeks post-injury in the rat model of ischemia-reperfusion injury [47].
This time window is promising for therapeutic intervention, with therapy to treat TBI
possibly having a greater chance of parenchymal uptake through this increased BBB
permeability.
The glial activation following injury activates the innate immune response, as
described in the earlier sub-section. This furthers the BBB dysfunction, with other
molecules contributing to the development of the leaky BBB, such as transforming
growth factor (TGF)-β, ROS, vascular endothelial growth factor (VEGF), matrix
metalloproteinases (MMP) and glutamate. This structural and physiological disruption,
together with the “no-reflow” phenomenon, allows the bidirectional movement of
inflammatory molecules across the BBB [23], [46].
The initial injury that leads to the plasmalemma damage in these cells is followed
by a loss of homeostasis causing the depolarization of neurons, giving rise to a spreading
calcium “depression” [37]. This ultimately results in the secondary axotomy described
earlier, the outcome of which is the loss of neural networks, thereby augmenting the
incidence of neurological deficits such as emotional responses, memory, locomotor
coordination, thus impacting the quality of life of the patient.
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2.2

Small Molecule Drugs and Peptide Therapeutics to Treat Traumatic Brain
Injury

2.2.1

Current Therapies for Traumatic Brain Injury
After over 30 clinical trials, none have produced sufficient evidence to obtain

FDA-approval for a pharmaceutical to treat TBI [48]. Current medical interventions for
TBI include non-specific approaches such as head elevation, hyperventilation, invasive
intracranial pressure monitoring, and as a last resort, decompressive surgery [49]. Owing
to the complex pathophysiology of TBI in the brain, it has been difficult to find a
promising drug that treats multiple stages in the cascade, therefore combination therapies
could be most effective. In 2019, the FDA qualified the first biomarker test OsiriX CDE
as a tool to better identify eligible clinical trial patients based on MRI images [50].
Studying the progression of the neuropathology accurately would require
neurobiological imaging. This can achieve cellular and molecular resolution but is not
typically done as it only possible with the use of post-mortem tissue, which is invasive,
thus undesirable. Owing to the complex pathophysiology of TBI in the brain, it has been
difficult to find a promising drug that treats multiple stages in the cascade, therefore
combination therapies could be most effective.
Several preclinical interventions have proven effective in rodents yet failed
clinical trials. These interventions include calcium channel blockers like Nimodipine
[51], and neuroprotective drugs like Tirilazad [52] and Cyclosporine [53]. Alternative
therapies such as the use of endogenous neural stem cells to improve motor and cognitive
functions has also been studied [54]. The use of anti-inflammatory therapies such as
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statins have been hampered by issues regarding adverse effects and timing [55].
Erythropoietin failed to produce beneficial effects in TBI patients [49], [56].
Increasing evidence points to the use of mild, transient immunosuppression by
blocking microglial activation. This use was supported by studies such as Cao et al. in
2012 [57] which suggested that high, sustained doses of anti-inflammatory drugs may
hinder the working of the neuroprotective inflammatory cascades. Therefore, emphasis
must be placed on the investigation of precise therapeutic windows for the mild dosing
but effective treatment, rather than prolonged treatment in the chronic phase of TBI
which could compromise the benefits of inflammation and neuronal recovery.
2.2.2

Blood-Brain Barrier Shuttle Peptides
TBI therapies tested to date have not emphasized crossing of the BBB. BBB

shuttle peptides/ peptide vectors are peptides that can transport cargo into the brain
without compromising the BBB integrity and they present a promising, viable solution to
TBI therapy by overcoming the disadvantages of cost, complex derivatization, and high
immunogenicity. Direct administration to the brain can be invasive, excessively
localized, and high-risk, but the use of the BBB shuttle concept capitalizes on various
transport pathways across the BBB, such as passive diffusion, adsorptive- mediated
transcytosis (AMT) or RMT [58]. RMT offers a higher advantage than the other
pathways because it is targeted, i.e., binding to specific ligands followed by uptake.
Many protein shuttles that bind to endothelium surface-receptors, such as
apolipoproteins (ApoA and ApoE), receptor-associated protein (RAP) and transferrin (Tf)
have been identified, but peptides have been designed to improve upon the specificity of
these biologics and are easy and cost-effective to synthesize. They also have a significant

15
advantage in that their structure, function, and immunogenicity can be modified by nonnatural amino acids, cyclization, conjugation to cargo and other strategies. Ideally, BBB
shuttle peptides should be targeted to receptors that have: 1) been highly characterized,
such as transferrin (TfR1) [59], low-density lipoprotein receptor (LDLR) family [60],
insulin [61] and leptin [62]; 2) high luminal-side expression, 3) high turnover rate and 4)
broad recognition of substrates [58].
In 2015, the humanin-derivative peptide AGA(C8R)-HNG17 was shown by
Cohen et al. to mitigate necrosis through a decrease in ATP levels in a mouse model of
TBI, thereby protecting against cell death [63]. However, this peptide was directly
injected into the spinal cord through the cisterna magna, not via a BBB-crossing delivery
mode. More recently, Ma et al. studied injectable self-assembling peptide-based hydrogel
for neovascularization in TBI [64]. This peptide hydrogel, SLanc, was directly injected
into the injury site immediately after FPI. While this method seems promising, it still
does not sufficiently address the problem of crossing the BBB without damaging it.
Figure 2-1 shows some features of BBB shuttle peptides that cross via the RMT
pathway.
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Table 2-1: Features of some BBB shuttle peptides that use the RMT mode of transport.
Peptide

Sequence

Proposed
transporter

Main cargoes

Ref.

Angiopep2

TFFYGGSRGKRNNFKTEEYOH

LRP1

[65]

ApoB
SSVIDALQYKLEGTTRLTRK(3371RGLKLATALSLSNKFVEGS
3409)
ApoE
(LRKLRKRLL)2
(159–
167)2
Peptide-22
Ac-C(&)MPRLRGC(&)-NH2

LRP2,
LDLR

Small drugs,
proteins,
nanoparticles,
nucleic acids
Proteins

Proteins,
nanoparticles

[67]

Nanoparticles

[68]

RNA and
nanoparticles

[69]

LRP1,
LRP2,
LDLR
LDLR

[66]

THR

THRPPMWSPVWP-NH2

TfR1

THR
retroenantio
CRT

pwvpswmpprht-NH2
C(&)RTIGPSVC(&)

TfR1

C(&)RTIGPSVC(&)

TfR1

Virus

[71]

Leptin30

YQQILTSMPSRNVIQISNDLENLRDLLHVL

Leptin
receptors

DNA

[72]

2.3

Small drugs and [70]
nanoparticles

Animal Models of Traumatic Brain Injury

Sincere efforts have been made by academic scientists to advance the
understanding of neurotrauma research, through the development of animal models to
replicate the pathophysiology and symptoms of TBI. It is imperative that animal models
be clinically relevant and closely model the neurobehavioral deficits in humans so that
therapies being tested having adequate functional outcomes. The prior observations
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underscore the need to develop appropriate models of animal TBI based on sex, age, and
severity. The four most common experimental models of TBI are: fluid percussion injury,
cortical impact injury, weight drop impact acceleration injury and blast injury [73]. Since
rodents have been popularly used due to their relatively low cost, small size, and
reproducible experimental outcomes, we used mouse models of TBI in this research.

RATIONAL DESIGN AND SYNTHESIS OF PEPTIDES
TO OPTIMIZE BBB - PENETRATION AND
INTRANASAL DELIVERY
3.1

Modes of Peptide Drug Administration

Most peptide or protein pharmaceuticals currently in use are traditionally
delivered by invasive routes [2]. Drug administration to the brain via invasive routes such
as intracisternal injection of bFGF to prevent the retrograde degeneration of thalamic
neurons [74] and direct injection (DI) of a peptide hydrogel to stimulate angiogenesis
[64] at the site of brain injury can prove to be more effective than non-invasive routes at
increasing the therapeutic drug concentration in the brain parenchyma. However,
significant problems can arise with these methods, such as the proximity of the injection
site to vital brain structures for the intracisternal method [75] and a need for surgery
conducted by experienced investigators to expose the dura through the DI route.
Traditional non-invasive drug delivery methods such as oral [76], buccal [77],
rectal [78] and pulmonary [79] routes have been studied for peptide delivery. They each
have specific barriers to efficacy such as poor absorption and high propensity for
gastrointestinal enzymatic degradation via the oral route. A drawback of parenteral routes
is that it requires trained professionals for safe administration. Via the intravenous (IV)
route, peptides such as bFGF [80] and BDNF [81] and have been successfully delivered
18
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with conjugation to a BBB delivery vector (a.k.a., a Trojan horse). In the absence of BBB
disruption, bFGF is not neuroprotective, compared to 80% reduction in infarct volume in
rat brains affected by stroke when conjugated to the delivery vector and administered
intravenously. This demonstrates the neuroprotective effects of these BBB Trojan horse
peptides [4].
BBB disruption to increase permeability is highly desirable in the facilitation of
drugs across the BBB, but it leads to the problem of the leakage of plasma proteins into
the brain and an increase in toxicity to the brain cells. Interestingly, the disruption of the
BBB during a TBI is unwanted but has the advantage of allowing some molecules to
cross that an intact BBB would usually exclude. In this regard, our Trojan horse peptides
have a distinct advantage of hypothetically entering the brain through 2 pathways - RMT
through the LRP1 receptor and direct crossing through the leaky BBB during the window
of transient barrier disruption.
3.2

Considerations for Intranasally-Delivered Peptides

To increase brain targeting and for relatively rapid access to the brain, IN delivery
is an excellent non-invasive form of administration. In 2004, Banks et al. reported that,
compared with IV administration, IN administration of radioactively labelled exendin (939), a glucagon-like peptide-1 (GLP-1) receptor antagonist to treat Alzheimer’s Disease
(AD), was four times more effective in delivery to the olfactory bulb, but three times
lower in delivery to the rest of the brain [82]. Except for the olfactory bulb, there was no
statistically significant distribution difference in the different brain regions. Another ADtargeted peptide, the fluorescently-labeled R8-Aβ(25-35)-PEI, reached a maximum
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peptide level in the brain after 6 h [83]. A similar study also intranasally delivered the
cell penetrating peptide wtNBD into the brains of AD transgenic mice [84]. The peptides
used in the above studies all have a common factor- the poly-positively charged
components- which can help them translocate from the olfactory epithelium in the nasal
cavity to the brain.
The IN pathway appears to be the most promising and advantageous route.
Attractive attributes include the relatively large surface area in the nose, the permeable
and vascular nature of the nasal cavity, the ability to avoid enzymatic degradation and
hepatic first-pass metabolism [85], and the simplicity of non-invasive drug
administration. Administration through this route allows for the rapid entry of the drug
into the CNS via the olfactory and/or extracellular trigeminal nerves that originate in the
nasal epithelium, giving the drugs direct access to the CNS and allowing them to reach
their associated receptors in various regions in the brain [86], [87]. The rostral migratory
stream [88] has also been hypothesized to facilitate entry of drugs into the CNS, however,
the relative contributions of these three pathways – olfactory, trigeminal and rostral
migratory stream have been debated.
Pharmacological considerations for IN peptides include molecular weight, shape,
solubility, charge, dose, and bioavailability. For IN considerations, molecular weight was
a major predictor for nasal mucosal absorption. There was a sharp decline in nasal
bioavailability for peptides larger than 1000 Da (5%), however, peptides with molecular
weight up to 6000 Da have been delivered via IN administration and can still be
efficacious due to their high potency [85]. In some IN drugs, pharmacokinetic parameters
such as time for maximal concentration (tmax), maximal concentration (Cmax) and area
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under the curve (AUC) values were comparable to that of parenteral administrations.
Another major advantage is the possible higher effectiveness of IN delivery of drugs in
rostral regions of the brain over caudal regions [89], which is beneficial to the aims of the
study because the cortical brain regions impacted by injury are located rostrally. Drug
formulations for IN delivery can also be easily tailored for better volume delivery, such
as the use of a nasal spray, resulting in higher bioavailability than that of drops, and the
use of permeation enhancers such as cyclodextrins [85].
3.3

Choosing Peptides for this Study

Peptides in this study were chosen based on the RMT pathway as it was a
promising uptake route for peptides, for reasons described previously (See Chapter 1).
Demeule et al. first discovered the Angiopep family of cell penetrating peptides (CPP)
derived from the Kunitz domain in 2008; in particular, Angiopep-2 (A2) has found to
have higher transcytosis capacity and parenchyma localization than aprotonin [65]. A2 is
a highly versatile peptide that has been studied to act as a vector for pharmacological
molecules such as small molecules as well as peptides. In addition, it effectively
transports nanocarriers such as liposomes and dendrimers, and could increase the brain
delivery of most constructs transported by it, from 1.5-to-3-fold in mice [58]. A2 employs
the RMT mechanism of transport using the LDL family of receptors to transport its
cargoes [65]. Therefore, it was a good positive control candidate for an uptake
comparison study for our new BBB shuttle peptide, L57. LRP1 of this LDL family is
ubiquitously expressed in the brain, with a high expression in neurons, microglia and
activated astrocytes [90]. It is also expressed in the cells of the NVU, i.e., the brain
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endothelial cells, vascular smooth muscle cells and pericytes, and also the choroid plexus
[91]. This high expression offers a vital advantage to BBB delivery using LRP1-mediated
RMT, which is the binding and uptake of LRP1-targeted peptides for efficient BBB
transcytosis.
Another CPP, Octoarginine (R8), was also chosen as a positive control peptide as
it has been previously shown to act as a brain delivery vector. It was shown to be taken
up when conjugated to a cargo as in the case of R8-Aβ(25-35)-PEI peptide [83] as well as
in the non-covalent delivery of insulin [92].
To increase the library of BBB-crossing vectors, we chose to study the peptide
L57, first developed by Sakamoto et al. as a potential RMT drug for the treatment of CNS
diseases [93]. They also studied the peptide Angiopep-7 (A7) in their original study and
compared it to L57. A7 is identical to A2, except that the lysine residues at positions 10
and 15 were replaced with arginine residues. The uptake and cytotoxicity data for the
potential Trojan horse peptide L57 and the positive control peptides A7 and R8 in an in
vitro brain model are reported in Chapter 4.
The purpose of the TBI therapy was to mitigate the progressive secondary injury,
which is exacerbated by inflammation. Therefore, an AIP was selected for conjugation to
the delivery vector, L57. This peptide was the main MK2 inhibitor sequence identified by
Hayess in 1997 – KKKALNRQLGVAA [94]. The sequence LARQLGVAA (note the N
was changed to A in studies subsequent to the original report) is essential for MK2
inhibition. To enable efficient intracellular delivery, Brugnano et al. in 2011 conjugated
it to diff. CPPs [95]. Several peptides containing this inhibitor sequence have been tested
previously in vitro in inflammatory models using RAW 264.7 and THP-1 cells, in vivo in
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lung fibrosis and vascular grafts, and ex vivo in bovine cartilage plugs. The most recent
work in this regard that showed significant promise was the Jiang et al. study in 2019
where this peptide was conjugated to a cell penetrating peptide. They used IN
administration to deliver it to the brain to attenuate Aβ1−42- and LPS-induced
neuroinflammation and memory impairments via the MK2 signaling pathway [86].
The L57 vector was covalently bound to the AIP sequence and fluorescently
labelled with FITC to obtain the peptide FLAP, with the L57 vector as a carrier for this
potentially anti-inflammatory peptide therapeutic. In our research, the peptide uptake and
localization in the brain for possible neuroprotective and regenerative effects was studied
in mouse models of TBI. Behavioral tests helped to assess the extent of the injury and
probable therapeutic effects of the peptide. Table 3-1 gives an overview of the peptides
used in this study. The results of the in vivo study are described in Chapter 5.

Table 3-1: Amino acid sequences of the peptides used in this study.
Peptides

Sequences a,b

Charge

MW

Fl-A7

Fluorescein-(Beta-ala)2TFFYGGSRGRRNNFRTEEY-CONH2

+2

2830.96

Fl-R8

Fluorescein-RRRRRRRR-CONH2

+8

1598.82

Fl-L57

FITC-Ahx-TWPKHFDKHTFYSILKLGKH-CONH2

+3

2985.75

FLAP

FITC-Ahx-TWPKHFDKHTFYSILKLGKH-(Betaala)-LARQLGVAA-CONH2

+4

3936.75

a All

sequences contain the L-forms of the amino acids. b Beta-ala in second and third sequences refers to beta-alanine
spacer. Ahx refers to 6-aminohexanoic acid spacer.
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3.4

Rational Design of Synthetic Peptides

Peptides can be designed according to their intended application. They can be
synthesized either de novo or based on native protein sequences (N-, C-terminals or
internal sequences). The amino acid sequence of peptides critically dictates their
physiochemical properties and the advantages of designing synthetic peptides are based
on the customized modification of their sequences. The use of synthetic peptides has
noteworthy advantages: the ease of synthesis, easily modifying their structures by the
incorporation of special amino acids (such as D-amino acids for retro-inverso peptides, or
cysteine residues for cyclization) and conjugation to groups such as antibodies and labels
for detection. The unique properties of peptides can thus be manipulated for a variety of
applications through the optimization of their biological activity, potency and uptake. In
the following sections, the key elements of peptide design are discussed and how they
were considered in the design of the peptides used in this study.
3.4.1

Length of Peptides
The length of a peptide can be varied according to its intended purpose. For

biological applications involving the delivery of a peptide into target tissue, peptides are
relatively small, usually smaller than the native proteins from which they were adapted.
Synthetic peptide lengths can range from as small as 2 amino acids (sugar substitute
aspartame [96]) to as large as hormones such as corticorelin acetate (41 amino acids [97])
and insulin (51 amino acids), considered to be the smallest known protein [98].
3.4.2

Molecular Weight of Peptides
100% of large molecule pharmaceutics and more than 98% of all small molecules

are excluded from crossing the BBB [4], therefore size is a crucial factor in the
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development of neuropeptides. Peptides are generally considered to be less than 5000 Da,
beyond which, they reach the scale of proteins [2], [98]. For example, insulin has a
molecular weight of 5800 Da [98]. Small drugs that are less than 300 Da, including
peptide shuttles of 3-4 amino acids in length can cross the BBB through passive diffusion
[58], i.e. non-selectively, without the need for RMT such as needed by larger
peptides/proteins [2]. Generally, the molecular weight of the drug should be <400 Da and
the drug should form <8 H-bonds to be a good candidate for CNS penetration through
lipid-mediated free diffusion [4]. The small size of peptides makes them a highly
attractive drug candidate in this regard.
3.4.3

Choice of Residues
To optimize peptide purity and solubility, care must be taken to minimize

Cysteine (C), Methionine (M) or Tryptophan (W) residues, which are prone to rapid
oxidation. C residues can be incorporated into the sequences with the goal of cyclization
of the peptide through their disulfide linkages, however, in this research, only linear
peptides were synthesized, thereby avoiding the need for C residues altogether. All
peptides were amphipathic (except for the Fl-R8 which was hydrophilic) but designed to
be soluble in water by incorporating less than 50% hydrophobic residues. Each peptide
had polar residues and hydrophilic, charged residues contributing to a net positive charge
at physiological pH which also assisted in improving aqueous solubility. The amphipathic
nature of these peptides aid in their intracellular delivery [99].
3.4.4

Terminal Groups
All the peptides used in this study were synthesized on the Rink amide resin using

traditional solid phase peptide synthesis (SPPS). This synthesis is carried out in the C to
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N direction and the use of the Rink amide resin ensures the formation of a C-terminal
amide. This strategy was used to improve peptide stability in plasma which can be done
either by N-acetylation or C-amidation, and to increase cell permeability. The Camidation also closely mimics the native protein which confers biological stability in
plasma [100]. Furthermore, in some natural peptides, this amidation can enhance peptide
recognition by the target receptor through hydrogen-bonding [100], [101].
3.4.5

Choice and Position of Fluorochrome
Modifying the linear peptide with a fluorochrome (fluorescent dye) allows for the

visualization of peptide uptake and localization in the observed tissue and wherever
applicable, protein binding. Fluorescein as well as its derivative Fluorescein
isothiocyanate (FITC) has been conjugated to linear peptides to study cell accumulation
and localization [95], [99], [102], [103] using microscopy techniques such as confocal
laser-scanning microscopy, epifluorescent microscopy and flow cytometry applications.
Due to the C-to-N direction of synthesis, FITC is commonly conjugated at the Nterminus. FITC at the N-terminus has been successfully studied for several peptides
without compromising their activity. The main disadvantage of using FITC is that it
photobleaches over short periods of time. For in vitro imaging, this problem was resolved
by focusing on one area of the well to set imaging parameters and then imaging an
adjacent area under the same settings of exposure, gain, and so forth. To further minimize
photobleaching, a custom-made antifade mounting medium was prepared and used (see
Appendix A).
The position of the fluorophore may affect the peptide function, and
efforts have been made to study the cellular uptake of the peptide with and without cargo

27
at different positions. For instance, Fischer et al. observed the internalization of cellpermeable peptides only for those labelled with fluorophores at their N-terminus using
various analogues derivatized with a fluorophore (either 5(6)-carboxyfluorescein or 5(6)carboxytetramethylrhodamine) [104]. At different positions, they added lysine residues
with side chains conjugated to the dye and found that N-terminal conjugation had the
highest internalization efficiency. Another study by Gurney et al. showed the importance
of peptide and fluorophore position, supporting the conclusion that conjugation of the
fluorophore (Rhodamine) at the N-terminus (fluorophore-peptide-cargo) did not
negatively alter the anti-inflammatory function of the CPP or its endosomal labeling
[105].
3.4.6

Ligand Attachment
A hydrophobic spacer molecule, such as aminohexanoic acid (Ahx) or Beta-

Alanine (β-Ala), can be used to physically separate the bulky fluorescent dye from the
peptide to which it is conjugated. The Ahx spacer in the peptide was introduced in
between the first amino acid and the thiourea bond between the isothiocyanate and amine
[106]. The hydrophobicity of the spacer also contributes to the amphipathic character of
the peptide and as such is omitted from the Fl-R8 peptide, which is purely hydrophilic.
The spacers Ahx or b-Ala have been successfully used during the generation of
fluorescently labeled peptides [83],[107], which enhances the stability of the fluorescent
label. The spacer also maintains the solubility, flexibility and mobility of the whole
molecule and reduces steric hindrance at the conjugation site of the fluorophore and the
main sequence, preserving peptide activity and function.
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3.5

Synthesis and Cleavage of Peptides by Solid Phase Peptide Synthesis

SPPS technology, first introduced by Merrifield [108], is based on the stepwise
addition of amino acids to a growing peptide chain using a solid phase support, inert resin
beads (in this project- polystyrene beads). This is the most common method of peptide
synthesis and is capable of yielding peptides up to 50 residues in length. The peptides are
synthesized from the C to N direction, where the first amino acid is coupled to the resin.
The resin has two functions: in 1) it acts as the C-terminal protecting group of the first
amino acid which is anchored to it, and 2) provides a solid support that keeps the peptide
chain bound during synthesis, coupling and wash steps, therefore eliminating tedious
purification steps after each coupling reaction as in liquid phase peptide synthesis. Linker
molecules attach the first amino acid at functional sites on the resin beads and Rink
linkers form peptide amides (CONH2 at the C-terminal). Peptide amides mimic the
natural structure while conferring more stability towards enzymatic degradation from
exopeptidases, an advantage in cell studies and in vivo experiments. The Rink Amide
resin has a loading factor of 0.61 mmol/g (number of linkers in millimoles per gram of
resin), which is good for peptides composed of fewer than 25 amino acids [109] (i.e. used
for Fl-R8, Fl-A7 in this study). The selection of this resin was also based on the
knowledge that lower substitution levels can improve synthesis [110]. Prior to synthesis,
the resin beads were swelled in dimethylformamide (DMF) for at least 30 minutes under
nitrogen gas agitation, to enable diffusion of reactants into the matrix core and maximize
the exposure of their functional groups to the incoming reactants. At each step, the
reaction/wash reagents were filtered by suction.

29
The main steps in the SPPS method are: 1) deprotection, 2) amino acid coupling,
3) washing, and 4) cleavage. They are described below.
3.5.1

Deprotection
In SPPS, which is dependent on the peptide synthesis by attaching amino acids

one by one, the amino acid is protected by N-terminal protecting groups (PG) to avoid
chain formation and at their unique side chains to avoid unwanted side products. The
most popular N-terminal PG is Fluorenyl-9-methoxycarbonyl (Fmoc) (see Figure 3-1).
Deprotection is the first step in synthesis involving the removal of this base-labile Nα-PG
protecting group from the Rink resin-linker and from each subsequent amino acid prior to
coupling with the new amino acid. This is done by treatment with organic bases
especially Piperidine (in this study) which is a secondary amine. The reaction proceeds
via an E1cb mechanism, the primary products being the carbamate salt and
dibenzofulvene (see Figure 3-2). For our peptides, Fmoc removal was done with 25%
Piperidine in dimethylformamide (DMF) solvent for 20-25 min. Fmoc chemistry is
popular as it requires mild reaction conditions and results in high yield and good quality
peptides.
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Figure 3-1: Fmoc chemistry. A. Fmoc group. B. Rink Amide resin protected at the NH
group by Fmoc. Deprotection of this Fmoc group is necessary before the first amino
acid is coupled. C. Amino acid protected at the N-terminal by the Fmoc group.

Figure 3-2: Deprotection of the Nα group of the amino acid by Piperidine. The E1cb
mechanism results in the formation of a dibenzofulvene intermediate, yielding a
piperidine adduct of the Fmoc group, and a deprotected amino acid.
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The side chain protecting groups are acid-labile, so they do not get cleaved during
this step, which is important for linear peptide synthesis proceeding in the correct
direction. They are permanent, orthogonal, and compatible with Nα protection. These
acid-labile PGs will be removed with TFA in the final peptide cleavage step, discussed
below in section 3.2.4.
3.5.2

Amino Acid Coupling
The crucial coupling step is the formation of the amide bond between two

successive amino acids. This reaction consists of two steps: 1) in situ activation of the
carboxy moiety and 2) acylation of the amino group.
3.5.2.1

Activation of the Carboxy Moiety on the Incoming Amino Acid
Activating of the carboxylic acid of the new N-protected amino acid must be done

to enable attachment to the amino group of the deprotected amino acid bound to the
peptide- resin. An excess of reagents (2-10 equivalents with respect to the resin) speed up
the coupling and minimize loss of configuration [111]. In our study, we used 2.5
equivalents of the amino acid and 1:1 ratio of amino acid to activator. The activator used
in this study was N-[(1H-benzotriazol-1-yl) (dimethylamino)methylene]-Nmethylmethanaminium hexafluorophosphate N-oxide (HBTU), which is an
aminium/uronium-based reagent and that converts the N-protected amino acids into their
corresponding OBt esters [109] (See Figure 3-3). HBTU as a coupling reagent is
advantageous as there are few undesired side reactions, in contrast to carbodiimide
activation. The resulting by-products are soluble in water and in organic solvents like
DMF. To enable efficient conversion, low levels of racemization and epimerization
[109], [112], 1-hydroxybenzotriazole (HOBt) was also added (2 equivalents). HOBt also
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enhances the reactivity of the activated ester by stabilizing the amine via hydrogenbonding [113]. An activating base- tertiary amine diisopropylethylamine (DIPEA) was
used at 3 times the amino acid equivalent, to help HBTU mediate amino acid coupling by
producing the carboxylate of the N-protected amino acid. One drawback of HBTU is that
it may produce unwanted side-products- tetramethylguanidinium derivatives of the amine
group on the peptide-resin [109], therefore, the activator-amino acid-base cocktail is
usually pre-activated in polar aprotic solvent DMF to produce the carboxylate for a few
minutes before adding the cocktail to the resin for coupling.

Figure 3-3: HBTU/ HOBt activation to get the corresponding HOBt ester of the amino acid.
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3.5.2.2

Acylation of the Amino Group of the Peptide
The second step involves the nucleophilic attack of the amino group (of the

growing peptide) to the activated carboxylate [111]. The activation in the first step results
in the formation of a derivative which contains a good leaving group, required for this
second step to enable the peptide bond formation (See Figure 3-4).
3.5.3

Washing
Washing is necessary after each step to prevent unwanted reactions such as

deprotection of the newly added amino acid during coupling from residual piperidine.
Washing is also necessary to eliminate byproducts such as urea and unreacted amino
acids after each coupling step. The primary solvent DMF was used to wash the resin,
followed by isopropyl alcohol (IPA) and DMF again to wash away the IPA and re-swell
the resin.
3.5.4

Fluorophore Labelling
As mentioned in Section 3.1.5, FITC was chosen as the fluorochrome, and all the

peptides synthesized for this study were labelled at the N-terminus with fluorescein or
FITC. After deprotection of the peptide with 25% Piperidine, the following reagents
(based on molar mass of the resin) were added together to form the fluorescein preactivation solution: 1.5 equivalents of fluorescein (disodium salt), 1.3 equivalents of
Dicyclohexylcarbodiimide (DCC), N-Hydroxysuccinimide (NHS) and 1.5 equivalents of
N-[(dimethylamino)-1H-1,2,3-triazolo[4,5-b] pyridin-1-ylmethylene]-N-methylmethanaminium hexafluorophosphate N-oxide (HATU).
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Figure 3-4: Solid phase synthesis scheme to obtain the fluorescently tagged peptide.
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These reagents were dissolved in DMF with an excess of DIPEA (5 equivalents
based on Fluorescein) and left to react for 3 hours. The end-product of this process is the
amine-reactive derivative of fluorescein- the fluorescein succinimidyl ester. Thereafter,
the solution was added to the resin along with 3 equivalents of DIPEA (based on resin)
for 3 hours to allow N-terminal labelling with fluorescein.
3.5.5

Cleavage of the Peptide
After the full peptide was synthesized and labelled, the peptide was removed

(cleaved) from the resin using trifluoroacetic acid (TFA), which also accomplishes the
removal of the acid-labile side chain PGs. This removal of PGs under acidic conditions
may inadvertently cause the alkylation of the exposed functional groups on the peptide
chain by cationic species. Scavengers are reagents that help to react with these free
species and therefore prevent their reattachment to the chain. Triisopropylsilane (TIPS)
and ethanedithiol (EDT) were added as scavengers in different ratios based on the peptide
sequence. The Fl-R8 peptide had a special cleavage cocktail for the removal of the Pbf
protecting groups from all the R residues (as suggested by the manufacturer, Aapptec,
and described in the peptide synthesis section in the next chapter). Cleavage was carried
out for 3-4 h and done twice on the resin to maximize yield.
3.5.6

Peptide Isolation
Post-cleavage, the peptide was filtered from the resin and dried under nitrogen

flow as much as possible, to obtain a concentrated peptide-TFA cocktail. Thereafter, icecold diethyl ether was added dropwise to precipitate the crude peptide, using 10 volumes
of ether per 1 volume of TFA-peptide cocktail. This was followed by lyophilization to
obtain dried peptides, finally stored at -20° C.
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3.5.7

Removal of TF-Acetate Counter-Ion
Lyophilization removes free TFA, but residual TFA counterions are left behind

and remain bound to the peptide, so peptides obtained via SPPS are usually TFA salts.
TFA has been found to act as a cell growth stimulator [114] or inhibitor [115],
introducing experimental variability that renders confusing results for growth and
cytotoxicity assays at concentrations above 10−9 M [115]. TFA anions bind to the free
amino terminus and basic residues (lysine, histidine, and arginine) [115]. Since all the
peptides used in this study are cationic (see Table 3-1 for net charge at pH = 7.0), the
TFA counterions needed to be exchanged for more biocompatible ions such as acetate or
chloride anions. However, the United States Pharmacopeia and European Pharmacopeia
require the measurement of levels of acetate anions in the final peptide drug as they are
regarded as impurities [116]. Therefore, even though peptides such as R8 have been used
in their original trifluoroacetate salt form without employing ion exchange [117], to avoid
any confounding results, we processed the peptides made in the lab (Fl-A7 and Fl-R8 )
using the reprotonation/reprotonation procedure proposed by Roux et al. [118], as
described below.
The peptide-TF-Acetate salt was dissolved in deionized water at 4° C to obtain a
concentration of 15 mg/ml. In solution, the positive charges of the side chains are
neutralized by the COO- groups of the TF-Acetate counter-ions. Both Fl-A7 and Fl-R8
contain only R residues – Fl-A7 has 4 R’s and Fl-R8 has 8 R’s- and the pKa of the R side
chain is 12.48. To precipitate the peptide from the solution, 1 M NaOH (pH = 14.0) was
slowly added, followed by incubation of the solution for 30 minutes at 4° C. The
resulting precipitate was then centrifuged at 2500 rcf for 5 min at 4° C and the
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supernatant was removed using a pipettor to rid the pellet of the TF-acetate-sodium salt.
To ensure full removal of the salt, the pellet was resuspended in deionized water and the
procedure repeated for a total of 6 times to obtain a neutral pellet devoid of any salt. This
pellet was finally resuspended in water and centrifuged under vacuum using a vacuum
concentrator (Eppendorf 5305 Vacufuge Plus Concentrator) to dry it due to the lack of
availability of a lyophilizer. Finally, the neutral peptide was dissolved in an acetate
solution containing double the number of acetic acid equivalents to molar mass of the
peptide, to prevent excess acid in the final peptide. The control of the amount of acetic
acid is a major advantage in this procedure.
All lyophilized peptides were aliquoted and stored in 2 mL tubes purged with
nitrogen at -20 °C. Whenever required for studies, the adequate amount of peptide was
reconstituted in the desired buffer and stock solutions were stored at 4 °C to avoid
repeated freeze-thaw cycles.
3.6

Characterization of the Peptides by MALDI-TOF

The molecular weights of the synthetic peptides were characterized by matrixassisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS).
The main advantage of this methodology is the minute quantity of samples required for
this highly sensitive spectrometric method. The samples are spotted on a plate with a
matrix solution, in our case, α-Cyano-4-hydroxycinnamic acid (4-HCCA) and operated in
the positive mode. The instrument used was a Bruker UltrafleXtreme MALDI TOF/TOF
mass spectrometer at Louisiana State University, Baton Rouge, USA.
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Figure 3-5: MS spectrum of Fl-L57 peptide ordered from Biomatik (FITC-AhxTWPKHFDKHTFYSILKLGKH-Amide). Expected mass: 2985.43, analyzed mass: 2985.75.

Figure 3-6: MS spectrum of FLAP peptide Fl-L57 peptide ordered from Biomatik
(FITC-Ahx-TWPKHFDKHTFYSILKLGKH-(Beta-ala)-LARQLGVAA-Amide).
Expected mass: 3936.75, analyzed mass: 3936.75.
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Figure 3-7: MALDI-TOF MS spectrum of Angiopep-7 (target sequence) unprotected
peptide (H2N-TFFYGGSRGRRNNFRTEEY-amide). Expected mass: 2356.52, analyzed
mass: 2359.11.

Figure 3-8: MALDI-TOF MS spectrum of R8 (target sequence) protected peptide
(Fmoc-RRRRRRRR-amide). Expected mass: 1488.76, analyzed mass: 1488.912.
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The spectra are shown in the Figure 3-5, Figure 3-6, Figure 3-7 and Figure 3-8,
for peptides Fl-L57, FLAP, A7 and R8 respectively.
All the peptides in this study were successfully synthesized. The MS spectrum for
each peptide confirmed the identification of the peptide and its impurities. Peptide
identification was done based on m/z values with each peak representing a cluster of ions
in the same charged state.

EFFICIENT LRP1-MEDIATED UPTAKE AND LOW
CYTOTOXICITY OF PEPTIDE L57 IN VITRO
SHOWS ITS PROMISE AS CNS DRUG
DELIVERY VECTOR
This chapter is based in full on the previously-published journal article, cited as:
J. P. Rodrigues, N. Prajapati, M. A. DeCoster, S. Poh, and T. A. Murray, “Efficient
LRP1-Mediated Uptake and Low Cytotoxicity of Peptide L57 In Vitro Shows Its Promise
as CNS Drug Delivery Vector,” J. Pharm. Sci., vol. 110, no. 2, pp. 824–832, 2021, doi:
10.1016/j.xphs.2020.09.019 [12]. It is reproduced here with permission from all the coauthors involved in this study.
4.1

Abstract

Although a plethora of drug candidates are aimed at the remediation of central
nervous system disorders, the utility of some is severely limited by their ability to cross
the BBB. Potential drug delivery systems such as the Angiopep family of peptides [65]
have shown modest potential; however, there is a need for novel drug delivery
candidates, especially those incorporating peptidomimetics to enhance the efficiency of
transcytosis, specificity, and biocompatibility. Here, we report on the first in vitro cellular
uptake and cytotoxicity study of a newly developed cationic peptide, L57. It binds to

42

43
cluster 4 (Ser3332–Asp3779) of the LRP1 receptor which is expressed in numerous cell
types, such as brain endothelial cells, and is crucial to the uptake of LRP1 ligands. We
used early-passage-number brain microvascular endothelial cells and astrocytes harvested
from rat pup brains that highly express LRP1, to study the uptake of L57 and to compare
it to that of Angiopep-7, another peptide that uses the LRP1 pathway as well as a cellpenetrating peptide R8. Furthermore, we observed very low levels of peptide uptake in
PEA 10 cells, which express reduced levels of LRP receptors. We found that overall,
cellular uptake of the L57, A7 and R8 showed a concentration-dependent increase, with
L57 being taken up to a greater degree than both A7 and R8 at the same concentration.
Moreover, excellent cell viability after the addition of the L57 peptide compared to the
other two peptides further cements the promise of this novel LRP1 ligand as a potential
drug delivery vector for central nervous system therapeutics. The reasons justifying the
choice of these peptides are explained in Chapter 2.
4.2

Introduction

The delivery of therapeutics into the brain for the remediation of specific central
nervous system (CNS) disorders is impeded by their suboptimal blood-brain barrier
(BBB) penetration. Macromolecules, such as proteins and nucleic acids, are prevented
from paracellular and transcellular transport by specialized CNS barriers such as brain
capillary endothelial cells of the BBB. This formidable challenge is one key reason why
these disorders remain largely untreated, despite the ready availability of effective
candidate drugs to treat them [119]. As such, effective modes of delivery are needed to
efficiently transport therapeutics across the BBB.
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Over the last decade, there has been a heightened interest in neuro-pharmaceutics
for CNS disorders, as reviewed in [4], [120]. Potential advantages of
neuropharmaceuticals include high specificity, potency, minimal cross-reactivity, low
immunogenicity, and relative ease of modification to optimize their pharmacokinetic
properties. Consequently, the pharmaceutical industry has made great strides in the
development of peptide therapeutics, with over 70 therapeutic peptides on the market and
more than 150 in clinical studies [120]. Therapeutics targeted to the brain can be
delivered through various routes of entry such as DI, IV, IN, or sub-cutaneous injection
[4], [120]. However, not all peptides cross the BBB [4]. More recent approaches have
incorporated the use of targeted nanoparticles to deliver therapeutic peptides to the brain
[121]. Small cationic peptides have been used in a Trojan horse-like approach to
remediate brain disorders such as using a SynB1 protegrin derivative to deliver
benzylpenicillin across the BBB [8] and treating ischemic brain damage using TatNR2B9c and pTat-PDZ1-2 [9]–[11].
Two well-characterized modes of peptide transport across the BBB are AMT and
RMT. Via the AMT mode, poly-lysine and poly-arginine peptides are translocated as
efficiently as Tat peptides [122]. Kamei et al. concluded that efficient transduction is
achieved for a peptide with eight sequential arginines (R8) in a mouse microvascular
endothelial model based upon bEnd.3 cells [92]. From experiments with bEnd.3 cells in
vitro and rat brains in vivo, they concluded that R8 was safe and effective for the noncovalent delivery of certain hydrophilic macromolecules such as the peptide drug insulin,
which inspired us to select this peptide as a positive control for our studies in the main
cells of interest, rat brain microvascular endothelial cells (BMVECs).
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As for the RMT mode, the cationic peptides A2 (TFFYGGSRGKRNNFKTEEY)
[123], [124] and its analogue A7 (TFFYGGSRGRRNNFRTEEY) cross the BBB in
mouse models [93], [124]. A2 and A7 are peptides derived from the Kunitz domain of the
low-density lipoprotein receptor-related protein 1 (LRP1) endocytic receptor [124] which
is expressed in many cell types including brain capillary endothelial cells [117], and is
enriched at the lipid rafts. LRP1 is also implicated in numerous biological processes such
as transcytosis of macromolecules such as receptor-associated proteins and matrix
proteins [125], [126]. In 2008, the uptake of ANG1005, an A2-Paclitaxel drug conjugate,
was found to exhibit high brain accumulation and anti-tumor efficacy in both in vitro and
in vivo animal models of brain and lung cancer, compared to the unconjugated Paclitaxel
drug [127], [128]. This conjugate has shown promising results in Phase II clinical trials
[121]. Two other A2 conjugates, ANG1007 and ANG1009, which use the anticancer
drugs doxorubicin and etoposide, respectively, have also been developed [129]. These
drugs induced cytotoxicity against human cancer cell lines such as NCI-H460 lung
carcinoma. A non-covalent mode of delivery has also been developed that carries
immunoglobulins to the brain using the K16ApoE synthetic peptide [130], [131].
The success of A2 peptide-drug conjugates in preclinical studies opened the door
to the discovery of the first artificial LRP1 ligand, the cationic peptide L57, which
specifically binds to cluster 4 of the LRP1 receptor. This peptide, developed by Sakamoto
et al. [93], is less basic than the well-studied cell-penetrating peptide R8; thus, there may
be a lower risk of non-specific binding. In their study, L57 showed significant BBB
permeability and higher LRP1 binding affinity over both A2 and A7. Moreover, A7 was
chosen as the reference peptide for their in vivo studies as it exhibited better BBB
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permeability than A2. This permeability factored into the decision to use A7 in our study
to compare it against L57. Importantly, Sakamoto et al. did not study the toxicity of the
A7 and L57 peptides in vitro (in a suitable BBB model such as BMVECs) or in vivo.
Furthermore, they did not provide an assessment of the levels of cellular uptake of these
peptides in various cells in vitro - which was addressed in the present study.
In this study, we used primary rat BMVECs to visualize the intracellular
accumulation and localization of the fluorescent L57, A7 and R8 peptides in vitro
through fluorescence microscopy. The principal reason we chose these cells was because
LRP1 receptors are highly expressed in brain microvessels in mouse pups [132]. Primary
cells also mimic the BBB better than cell lines as immortalized cells have lost the
capability to form tight junction barriers [133], issuing a loss in the BBB-specific
permeability characteristic. Furthermore, BMVECs are the brain’s first structural barrier
to the CNS; thus, these cells provide a suitable in vitro model to compare uptake and
potential cytotoxicity of peptide carriers. We quantified the uptake of various
concentrations of these peptides and reinforced the observations made by Sakamoto et al.
that L57 peptides exhibited better cell uptake than A7, with our observations being made
in BMVECs compared to their brain perfusion assay in mice. We also compared the
cellular uptake of these peptides in two other cell types, LRP1-expressing brain
astrocytes (another key component of the BBB) and PEA 10 cells (LRP1-deficient cells)
[134], with varying, but still encouraging, results. We also conducted cytotoxicity testing,
which was previously unstudied. Our results showed that L57 has greater
biocompatibility than both A7 and R8 peptides in BMVECs and PEA 10 cells. In
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summary, our results suggest that the L57 peptide could be a promising new carrier to
more effectively deliver CNS therapeutics to the brain.
Materials and Methods
4.2.1

Materials
The fluorenylmethoxycarbonyl (Fmoc)-protected amino acids, Rink Amide AM

resin, 1-hydroxybenzotriazole (HOBt), O-(benzotriazol-1-yl)-N,N,N’,N’tetramethyluronium hexafluorophosphate (HBTU) and O-(7-azabenzotriazol-1-yl)N,N,N’,N’-tetramethyluronium hexafluorophosphate (HATU) were purchased from
Aapptec (Louisville, KY, USA). N,N-diisopropylethylamine (DIPEA) was acquired from
Sigma-Aldrich (St. Louis, MO, USA). Fluorescein (disodium salt) and diethyl ether was
purchased from Fisher Scientific (Hampton, NH, USA). N,N-dimethylformamide (DMF),
N, N’-dicyclohexylcarbodiimide (DCC), 99%, isopropyl alcohol (IPA), triisopropylsilane
(TIPS), N-hydroxysuccinimide (NHS), 1, 2-thanedithiol (EDT) and TFA, 99% was from
MilliporeSigma (St. Louis, MO, USA). Anisole and thioanisole were purchased from TCI
America (Boston, MA, USA). Dimethyl sulfoxide (DMSO, cell culture grade) was
bought from MP Biomedical (Irvine, CA, USA).
4.2.2

Peptide Synthesis
L57 (FITC-Ahx-TWPKHFDKHTFYSILKLGKH-CONH2) was custom-made by

Biomatik (Cambridge, ON, Canada).
Angiopep-7 (A7, TFFYGGSRGRRNNFRTEEY-CONH2) and R8 (RRRRRRRCONH2) were synthesized by Fmoc-based solid phase peptide synthesis methodology
(see Figure 3-4). First, Rink amide AM resin was swollen with DMF. For Fmoc
deprotection, 25% piperidine in DMF was added to the resin, under nitrogen bubbling for
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20-25 min. The resin was washed with DMF (3x), IPA (2x) and DMF (3x). For each
amino acid coupling, 2 equivalents (eq.) of HOBt, HBTU (2.5 eq.) and DIPEA (6 eq.)
was added to 2.5 eq. of Fmoc-amino acid in DMF. Nitrogen was bubbled for 3-4 h and
resin was washed with DMF (3x), IPA (2x) and DMF (3x). A7 was also coupled to a
spacer -two Beta-alanine amino acids- using the same strategy. Both A7 and R8 peptides
were then fluorescently tagged with fluorescein at the C-terminal. This was done by first
activating the fluorescein with NHS (1.3 eq. based on fluorescein), DCC (1.3 eq. based
on fluorescein), HATU (1.5 eq. based on resin), and DIPEA (5 eq. based on fluorescein)
in DMF for 3 h under stirring. The activated fluorescein-NHS ester was then transferred
to the main vessel together with 3 eq. of DIPEA for another 3 h. Final fluorescently
tagged A7 (Fl-A7) was washed with DCM (3x) and cleaved from the resin with a cocktail
of TFA (98% v/v), TIPS (1% v/v) and distilled water (1% v/v). Cleavage of fluorescently
tagged R8 (Fl-R8) was carried out with a cocktail of TFA (90% v/v), thioanisole (5%
v/v), EDT (3% v/v), and anisole (2% v/v). The cleaved mixture was concentrated under
vacuum and precipitated dropwise in cold ether, centrifuged, frozen in water then
lyophilized. Peptide molecular weight was confirmed by matrix-assisted laser desorption
ionization time-of-flight (MALDI TOF) mass spectrometry with a Bruker UltrafleXtreme
MALDI TOF/TOF mass spectrometer at LSU, Baton Rouge, USA (See Figure 3-5 to
Figure 3-8 for the spectra).
4.2.3

Animal Care and Harvesting of Primary Rat BMVECs and Astrocytes
Pregnant Sprague Dawley dams were maintained in a 12-h day-light cycle and

provided with food and water ad libitum. Rat pups remained with the dam until sacrificed
by cervical disarticulation between post-natal day 1-3. All procedures were conducted
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according to a protocol approved by the Louisiana Tech University Animal Care and Use
Committee.
Cells were isolated from the cortex of Sprague–Dawley pups (2-4 days) and
cultured in F12 Nutrient Mixture containing 10% Fetal Bovine Serum, 10% Horse
Serum, and other components (heparin, glutamine, NaHCO3), as previously described
[135], [136]. The glial cells thus obtained are purified by treating them with 5.51 µM of
Puromycin (MilliporeSigma, St. Louis, MO, USA) and cultured in rat endothelial cell
growth medium with endothelial growth factors to obtain BMVECs alone [137], [138].
Rat brain astrocytes are obtained by subculturing the glial cells in Ham’s F-12K medium
containing 5% horse serum and 5% FBS and washing off the overlaying microglial cells
a few times before being subcultured.
Cells were plated at a density of 10,000 cells per well onto poly-L-lysine-coated
96-well black-walled cell culture plates (Corning Costar), and grown at 37° C, in 5%
CO2 in humidified incubators. Cells were grown for 24 h then used for cell uptake and
cytotoxicity studies at 50%-70% confluency. Cells were tested at early passage numbers
(not tested after passage 9) so that efficient BBB model characteristics could be retained
[139].
Mouse embryonic fibroblasts (PEA 10) that are heterozygous for LRP receptor
expression were purchased from ATCC (Manassas, VA, USA). These were used to study
the effect of LRP deficiency on the uptake of these LRP1-targeted peptide ligands [134].
4.2.4

Visualization of Peptide Uptake and Intracellular Distribution
Fl-A7 was initially dissolved in a minimal volume of DMSO, 20 µl, and then this

solution was diluted in endothelial cell media to prepare working concentrations of 10, 30
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and 100 µM. Fl-L57 and Fl-R8 were dissolved in distilled water and then in endothelial
media. Fl-L57 was prepared at 3, 10, and 30 µM. Fl-R8, our positive control, was
prepared at 30 µM concentration. Each concentration was tested in two separate passages
of cells, in triplicate wells of 96-well plates. For each test, six wells containing cells with
no peptide were used as negative controls. Of these, three wells with media were used as
control wells for the Fl-L57, and three wells contained 0.5 % DMSO in media (equivalent
amount of DMSO as the 100 µM Fl-A7) control wells for the Fl-A7. For each peptide
concentration, the media in the corresponding well was exchanged with the peptide
media. After all the peptides were added to the respective wells, the plates were incubated
for 4 h at 37° C, in 5% CO2 in humidified incubators. After the incubation period, the
cells were washed twice with warm phosphate buffered saline (PBS) and once with
phenol red-free RPMI media and then fixed for 10 min with paraformaldehyde. We used
one wash because excessive washing possibly compromises cell membrane integrity
[140]. After fixation, the cells were washed once with PBS, and then stored for imaging
in PBS. Some cells were also stained with DAPI nuclear counterstain to visualize the
individual cell nuclei.
Epifluorescence images of FITC-labeled peptides and DAPI were acquired at
three random locations at 20X magnification in both fluorescence (FITC: 470 nm
excitation, 530 nm emission; DAPI: 358 nm excitation, 461 nm emission) and phase
contrast images using a Leica DMI 6000B inverted microscope with a DP71 color
camera (Leica Microsystems, Wetzlar, Germany) and at consistent equipment settings
and controls. A few time-lapse image sets of live cells were acquired to show dynamics
of uptake. Images were saved as TIFF files for analysis.
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4.2.5

Quantification of Fluorescence Intensity
Mean fluorescence intensity from FITC emission was used to compare levels of

peptide uptake. Cells in TIFF images were analyzed by first setting the background
fluorescence for each image as a threshold value using FIJI software (ImageJ) [141],
[142] and then selecting regions of interest using random assignment but taking care to
avoid regions with undissolved fluorescent peptide aggregates. Finally, the corrected
mean fluorescence intensity was calculated in relative fluorescence units (rfu) according
to the formula:
Corrected mean fluorescence intensity (in rfu) = mean fluorescence of cell - mean
fluorescence of background
For each treatment, two experimental trials were conducted with triplicate wells,
and the corrected mean fluorescence intensity was calculated for 20 cells in each well, for
a total of 120 cells. For each well incubated with peptide, this value was normalized to
the mean of the vehicle control wells to obtain the normalized fluorescence intensity
(NFI). There was no significant difference between cells incubated in the vehicle with
DMSO versus without it; thus, these results were grouped together.
4.2.6

MTT Assay
The MTT assay, which measures cytotoxicity by comparing cellular metabolic

activity, was performed as described previously by Vives et al. [143]. Cells were cultured
in poly-L-lysine-coated 96-well black-walled cell culture plates in humidified incubators
at 5% CO2 and 37 °C temperature for 24 h. The cells were then treated with varying
concentrations of the Fl-L57, Fl-A7 or Fl-R8 peptides. Control wells for Fl-L57 and FlR8 received media with no peptide. Control wells for Fl-A7 received media with no
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peptide, but with DMSO equivalent to that in the highest concentration (100 µM) of FlA7. After 4 h, MTT (1.25 mg/ml in RPMI media) was added and incubated for 1.5 h in a
37° C incubator. The resulting formazan product was dissolved in 90% isopropyl alcohol
and absorbance was read at 570 nm. The absorbance values of peptide-treated wells were
normalized to the mean absorbance of wells incubated with the respective vehicle.
4.2.7

Statistical Analysis
Statistical comparisons for the cellular uptake assay were performed using one-

way ANOVA with Tukey’s (comparisons between groups) for the fluorescence intensity
data and Dunnett’s (compared to control) post hoc correction for the cytotoxicity assay.
For comparisons between two groups, two-tailed t-tests were performed. All statistical
tests were performed using GraphPad Prism version 8.3.0 for Windows (GraphPad
Software, San Diego, California USA, www.graphpad.com). Results were considered
statistically significant when p < 0.05. Values are represented as mean ± standard error of
the mean (SEM) of n = 6 wells for each treatment condition.
4.3
4.3.1

Results

Internalization of FITC-Labeled Peptides
Images that show the cellular uptake of the two fluorescently labeled peptides Fl-

L57 and Fl-A7 are shown the figures below. Peptides were incubated with the cells over
four hours. Figure 4-1 shows uptake in microvascular endothelial cells, Figure 4-2
shows uptake in astrocytes, and Figure 4-3 shows uptake in PEA 10 cells. The left
column is the fluorescent image alone. The middle column is the fluorescent image
superimposed on a DAPI-stained image that shows the locations of the nuclei. The right
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column is a phase contrast image of the cells. Cells incubated with Fl-L57 (Panels A, B
and C) displayed diffuse staining throughout the cells for all three cell types. Incubation
with 100 µM Fl-A7 exhibited high uptake by the two primary brain cell types (Panels G-I
of Figure 4-1 and Figure 4-2) but low uptake by PEA 10 cells (Figure 4-3G-I). In
BMVECs, the fluorescence was saturated when incubated with 30 µM Fl-L57; therefore,
these results were excluded from analysis for this cell type. BMVECs showed the highest
uptake efficiency for the Fl-L57 and Fl-A7 peptides, followed by astrocytes and then
PEA 10 cells. The Fl-R8 peptides also labelled the nucleolus and exhibited punctate
staining possibly indicative of endocytic staining, as previously observed by fluorescence
microscopy [140].

54

Figure 4-1: Uptake of fluorescein-labeled L57 (Fl-L57) and A7 peptides (Fl-A7) in
cultured rat brain microvascular endothelial cells (BMVECs). Panels A-F:
Representative image set of cells incubated with Fl-L57 (10 µM) (panels A-C) and
vehicle (panels D-F) for 4 h. A. BMVECs after incubation with Fl-L57 (green). B.
Image in A (green) was merged with image of DAPI-counterstained nuclei (blue). C.
Phase contrast image of the same cells shown in A-B. D. BMVECs incubated with
vehicle. E. Image in D was merged with image of DAPI-counterstained nuclei (blue).
F. Phase contrast image of the same cells shown in D-E. Panels G-L: Representative
image set of cells incubated with Fl-A7 (100 µM) (panels G-I) and vehicle (panels J-L)
for 4 h. G. BMVECs after incubation with Fl-A7 (green). H. Image in G (green) was
merged with image of DAPI-counterstained nuclei (blue). I. Phase contrast image of
the same cells shown in G-H. J. BMVECs incubated with vehicle. K. Image in J was
merged with image of DAPI-counterstained nuclei (blue). L. Phase contrast image of
the same cells shown in J-K. Scale bar represents 30 µm.
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Figure 4-2: Uptake of fluorescein-labeled L57 (Fl-L57) and A7 peptides (Fl-A7) in
cultured rat brain astrocytes. Panels A-F: Representative image set of cells incubated
with Fl-L57 (10 µM) (panels A-C) and vehicle (panels D-F) for 4 h. A. Astrocytes after
incubation with Fl-L57 (green). B. Image in A (green) was merged with image of
DAPI-counterstained nuclei (blue). C. Phase contrast image of the same cells shown in
A-B. D. Astrocytes incubated with vehicle. E. Image in D was merged with image of
DAPI-counterstained nuclei (blue). F. Phase contrast image of the same cells shown in
D-E. Panels G-L: Representative image set of cells incubated with Fl-A7 (100 µM)
(panels G-I) and vehicle (panels J-L) for 4 h. G. Astrocytes after incubation with Fl-A7
(green). H. Image in G (green) was merged with image of DAPI-counterstained nuclei
(blue). I. Phase contrast image of the same cells shown in G-H. J. Astrocytes incubated
with vehicle. K. Image in J was merged with image of DAPI-counterstained nuclei
(blue). L. Phase contrast image of the same cells shown in J-K. Scale bar represents 30
µm.
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Figure 4-3: Uptake of fluorescein-labeled L57 (Fl-L57) and A7 peptides (Fl-A7) in
cultured PEA 10 cells. Panels A-F: Representative image set of cells incubated with FlL57 (10 µM) (panels A-C) and vehicle without peptide (panels D-F) for 4 h. A. PEA 10
cells after incubation with Fl-L57 (green). B. Image in A (green) was merged with
image of DAPI-counterstained nuclei (blue). C. Phase contrast image of the same cells
shown in A-B. D. PEA 10 cells incubated with vehicle. E. Image in D was merged with
image of DAPI-counterstained nuclei (blue). F. Phase contrast image of the same cells
shown in D-E. Panels G-L: Representative image set of cells incubated with Fl-A7
(100 µM) (panels G-I) and vehicle (panels J-L) for 4 h. G. PEA 10 cells after
incubation with Fl-A7 (green). H. Image in G (green) was merged with image of
DAPI-counterstained nuclei (blue). I. Phase contrast image of the same cells shown in
G-H. J. PEA 10 cells incubated with vehicle. K. Image in J was merged with image of
DAPI-counterstained nuclei (blue). L. Phase contrast image of the same cells shown in
J-K. Scale bar represents 30 µm.
The time course of Fl-L57 uptake was rapid for both BMVECs and astrocytes.
Fluorescence was monitored in real time with numerous cells exhibiting increases in
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fluorescence within the first minute of incubation. Figure 4-4 shows the time course for
BMVECs, where Panel A is fluorescence immediately after exposure to the peptide and
Panel B is fluorescence one minute later. Cells initially had only perinuclear localization
(Figure 4-4A, arrowheads) that redistributed throughout the cell (Figure 4-4B,
arrowheads). This redistribution was a gradual, and sometimes rapid, increase in
fluorescence spreading radially throughout the cell cytoplasm (Supplementary time-lapse
videos, V1 and V2). However, this phenomenon was not observed in the PEA 10 cells.

Figure 4-4: Time course images show uptake and distribution of Fl-L57 in BMVECs.
Representative images of live cells incubated with Fl-L57 at 10 µM over the first 1
minute of incubation (panels A-C) and vehicle (panels D-E). A. Image of cell culture
well immediately after adding Fl-L57. B. Visualization of Fl-L57 in the same well at
1 minute after exposure shows uptake by BMVECs. C. Phase contrast image of the
same cells in A-B. Supplementary time-lapse videos (V1 and V2 in [12]) show the
dynamics of peptide uptake in cells. D. BMVECs without peptide. E. Phase contrast
image of the same cells shown in D. Scale bar represents 30 µm.
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4.3.2

Quantification of Cellular Uptake of the Peptides
NFI was used to quantify the relative fluorescence levels from cellular uptake of

Fl-L57 and Fl-A7. Fl-R8 also exhibited significant uptake and, therefore, was useful as a
positive control in BMVECs. These values are plotted in Figure 4-5 for Fl-A7 at
concentrations of 10, 30, and 100 M and for Fl-L57 at concentrations of 3, 10, and 30
M. Data are shown for the three cell types, BMVECs, astrocytes, and PEA 10.
Internalization of Fl-A7 was concentration-dependent, with 100 µM Fl-A7 producing
significantly more uptake than 10 µM (p < 0.0001 for all cell types) and 30 µM Fl-A7 (p
= 0.013 for BMVECs, p = 0.0002 for astrocytes and p = <0.0001 for PEA 10 cells).
Likewise, in the BMVECs and astrocytes, cellular uptake of Fl-L57 scaled with
concentration. Incubation with 10 µM Fl-L57 resulted in an approximately two-fold
higher NFI versus incubation with 3 µM of the peptide in all cell types. Overall, PEA 10
cells had markedly lower uptake efficiency compared to BMVECs, and much lower
uptake compared to astrocytes at higher concentrations.
To determine the difference in uptake efficiency between Fl-L57 and Fl-A7, we
compared them at the same concentration (10 µM) across all the cell types tested.
Consistent with an in-situ study [93], Fl-L57 demonstrated significantly better uptake
overall. We observed significant differences between NFI of 10 µM Fl-L57 and 10 µM
Fl-A7 when incubated with BMVECs (p = 0.0082) and astrocytes (p = 0.013) but not
PEA 10 cells (p = 0.075). In addition, significant differences were seen between NFI of
30 µM Fl-L57 and 30 µM Fl-A7 when incubated with astrocytes (p < 0.0001) and with
PEA 10 cells (p = 0.018).
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Figure 4-5: Peptide uptake is concentration-dependent across the three cell types
tested – BMVECs, astrocytes and PEA 10 cells. Normalized fluorescence intensity
(NFI) was used to compare peptide uptake. Cells (10,000/well) were incubated with
various concentrations of the three peptides Fl-A7, Fl-R8 and Fl-L57 for 4 h and then
fixed. The fluorescence intensity of the peptides was quantified using ImageJ/FIJI
software and then normalized to controls. Fl-R8 images were taken at different
exposure; therefore, comparison is not shown. Twenty cells were randomly selected
per well (n=6 wells), for a total of 120 cells per peptide concentration (error bars
denote mean ± SEM). In BMVECs, the fluorescence was saturated when incubated
with 30 µM Fl-L57; therefore, these results were excluded from analysis (orange
asterisk). Statistical analysis was performed using one-way ANOVA with Tukey’s
post hoc comparisons between all groups. For comparisons between two groups, twotailed t-tests were performed. Horizontal colored bars represent comparisons of
peptide concentrations within the same cell types (color corresponds to cell type).
Black bars represent comparisons of peptide concentrations between different cell
types. * p < 0.05, ** p < 0.01, *** p < 0.001.
4.3.3

Cytotoxicity of Peptide Uptake
The MTT assay results are presented in Figure 4-6. BMVECs had high viability

when incubated with Fl-L57 and with Fl-R8 (Panel A), as did PEA 10 cells when
incubated with Fl-L57 (Panel B). In contrast, viability for both BMVECs and PEA 10
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cells incubated with Fl-A7 significantly decreased in a concentration-dependent manner.
For BMVECs, the p values were p = 0.015 for 10 µM,), p = 0.0001 for 30 µM and p <
0.0001 for 100 µM, and for PEA 10 cells the p values were p = 0.017 for 30 µM and p =
0.0002 for 100 µM Fl-A7.

Figure 4-6: Viability of cells after incubation with Fl-A7 and with Fl-L57. BMVECs
(A) and PEA 10 cells (B) were seeded at 10,000 cells per well and then incubated
with Fl-A7, FL-L57, or Fl-R8 (in BMVECs only) peptides, or vehicle, for 4 h. An
MTT assay was carried out to assess cellular metabolic activity. The y-axis represents
% cell viability normalized to viability of vehicle-treated cells (n = 6 wells, error bars
are mean ± SEM). For the Fl-A7 peptides, media with 0.5 % DMSO concentration
(corresponding to that in 100 µM Fl-A7) was used as the vehicle. Statistical analysis
was performed using one-way ANOVA with Dunnett’s post hoc correction. For
BMVECs ANOVA F (7, 38) = 12.8, p < 0.0001). For PEA 10 cells, ANOVA F (6,
35) = 14.5, p = 0.0017. P values for pairwise comparisons are * p < 0.05, ** p < 0.01,
*** p < 0.001, **** p < 0.0001.
4.4

Discussion

The primary goals of this study were to assess the efficiency of uptake of the
novel artificial LRP1-binding peptide L57 in primary BMVECs, and to compare this to
previously studied cationic peptides, A7 and R8, which are known to cross the BBB [92],
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[93]. Cellular uptake and cytotoxicity of Fl-L57 were evaluated in vitro for the first time
in BMVECs, which are crucial for uptake of this peptide due to their high expression of
the LRP1 receptor and location in the microvasculature of the brain. BMVECs are a
suitable BBB model owing to their enhanced tight junction complexity and monolayer
tightness, which demonstrates their ability to demonstrate characteristics of the brain
more closely than animal-derived cell lines and immortalized human BMVECs [133].
Astrocyte end feet cover 90–98% of the surface area of the brain microvasculature [4].
Thus, astrocytes were also used to evaluate the uptake efficiency of these peptides. The
BMVECs and astrocytes used in this study were not from cell lines, they were early
passages from freshly harvested cells from rat pups; therefore, they closely mimic BBB
phenotype. Our study provides a foundation for more extensive cellular uptake studies in
BBB models using this peptide. A key observation made in this study is the significantly
higher uptake of Fl-L57 versus Fl-A7 at the same concentration (10 µM) in all three cell
types tested, suggesting that when compared to other LRP1 binding peptides, we may see
similar or improved drug delivery of CNS therapeutics complexed with L57.
The third cell type we employed was the genetically modified PEA 10 cell line,
which is heterozygous for the LRP1 gene. It has one wild-type and one disrupted allele,
and it expresses approximately half of the wild-type level of LRP1 [134]. This cell line
was selected to determine whether the LRP-1 receptor is required for endocytosis of FlL57 and Fl-A7. The greatly reduced uptake of Fl-L57 and Fl-A7 by LRP1-deficient PEA
10 cells compared to BMVECs and astrocytes with high levels of LRP expression
strongly suggests that these peptides are internalized via a LRP1-mediated mechanism.
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The mode of internalization of L57 was through interaction with the cluster 4
(Ser3332–Asp3779) of LRP1 receptor, as studied by Sakamoto et al., using diversified
peptide libraries displayed on T7 phages [93]. Our choices of R8 and A7 were manifold.
R8 was chosen as the positive control for comparing peptide internalization, due to its
ability to efficiently internalize and even transcytose through the BBB when used both in
vitro [144] and in vivo [92]. On the other hand, A7 is an LRP1-binding peptide like L57;
although, it lacks sequence homology to L57. The two positive charges of the A7 peptide
and LRP1 binding mechanism are mainly responsible for the transcytosis of A7 across
the BBB [93], [124]. The L57 peptide is similarly cationic and binds to the LRP1
receptor. Thus, it can be postulated that the same factors are responsible for the
transcytosis of L57, in addition to the advantages of possibly having a reduced risk of
non-specific binding and being stable in mouse plasma [93]. Another group used A7 as a
negative control due to its lack of in vivo transcytosis [124]. However, Sakamoto
concluded that A7 demonstrated “comparable or slightly better BBB permeability than
Angiopep-2” when used as a reference peptide in their in-situ brain perfusion study [93].
Therefore, these conflicting results compelled us to use A7 in this preliminary study to
gather further information on the utility of this peptide for delivery to the brain.
The MTT assay suggested excellent viability of cells incubated with Fl-L57,
which further supports its potential for drug delivery studies in CNS diseases. The
metabolic activities of the cells were normal for Fl-L57 and Fl-R8 (Figure 4-6A) and
suggests that these peptides would not have adverse effects on the metabolism of cells at
the concentrations studied. In contrast, Fl-A7 induced cytotoxicity in a concentrationdependent manner in both cell types (Figure 4-5A-B). This was unexpected because A7
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has been studied before; however, its cytotoxicity was not evaluated in non-cancerous
cells prior to the present study. Given its greater internalization and the lack of
cytotoxicity, it appears that L57 would be more suitable as a delivery vector than A7,
particularly if higher concentrations of the peptide are required. Furthermore, our results
suggest caution when using A7 for IV delivery of drugs.
Our real-time observation of spreading fluorescence seen in live BMVECs
(Figure 4-4 and Supplementary Videos V1 and V2 in [12]) and astrocytes incubated with
Fl-L57 warrants further study. One possible explanation is that this pattern of punctate
staining was indicative of peptide localization in endosomes. These peptides would then
undergo endosomal escape into the cytoplasm (seen by the spreading fluorescence),
thereby overcoming degradation by being shuttled to the lysosomes. Notably, this
phenomenon was not observed for Fl-A7 or Fl-R8 in live cells. Future studies could
provide valuable insight into the length of time needed for BMVECs and astrocytes to
internalize the peptide and the intracellular route of internalized Fl-L57. The ability to
monitor trafficking of Fl-L57 in these cell models will enable future studies of the peptide
when conjugated or complexed with therapeutic compounds.
In summary, we tested the first artificial LRP1-binding peptide, L57, developed
by Sakamoto et al. in suitable in vitro models, rat BMVECs and astrocytes, and
discovered that this peptide has concentration-dependent uptake. Reduced uptake in
LRP1-deficient PEA 10 cells strongly suggests that Fl-L57 and Fl-A7 uptake is mediated
by LRP1-receptors. The Fl-L57 peptide also shows excellent cell viability, suggesting it
could be an efficient and safe vector for CNS therapeutics. The unexpected, yet exciting
real-time fluorescence phenomenon we observed for internalization of the L57 peptide
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can be used to gain insight into cellular uptake of this peptide in vitro, whether alone or
conjugated to potential therapeutics. Testing different modes of administration and
uptake of a variety of therapeutics could be used to further evaluate L57’s
pharmacokinetic properties. Further experiments are necessary to compare the BBBpenetrating ability of Fl-A7 vs. Fl-L57 at higher concentrations and determine the
optimal dose of each peptide.

EVALUATION OF THE PEPTIDE FL-L57 AS A BBB-CROSSING
THERAPEUTIC IN A MOUSE MODEL OF
TRAUMATIC BRAIN INJURY
5.1

Introduction

Trauma of the CNS affects at least 3 protein signaling cascades – MAPK, Akt and
GSK. These promote a diversity of functions such as memory, plasticity, motor skills and
the regulation of cell fate. MAPKs are activated by phosphorylation through mitogenic
signals. The signal transduction cascades are composed of extracellular signal-regulated
protein kinase (ERK), c-Jun NH(2)-terminal kinase (JNK), and p38 mitogen-activated
protein (p38) pathways, all responsible for cell growth and regulation, through the gene
regulation of downstream nuclear targets [145] (See Figure 5-1).
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Figure 5-1: Mitogen-activated protein kinases (MAPKs) regulate gene expression
through signal transduction. From Otani et al. [145].
An existing anti-inflammatory peptide (AIP) is known to inhibit mitogenactivated protein kinase activated protein kinase 2 (MK2), which is a downstream kinase
of the p38 mitogen-activated protein kinase (MAPK) signaling pathway [146]. This
pathway is an intracellular inflammatory cascade that contributes to neuroinflammation
in the brain via the increase of cytokine production; therefore, we expect that suppression
of MK2 activity via AIP could also downregulate inflammatory cytokines such as IL-6
and TNF-α. Jiang et al. have demonstrated that the IN administration of this AIP, via
conjugation to a CPP downregulates the MK2 pathways, thereby ameliorating LPS- or
Aβ1−42-induced neuroinflammation in vitro and in vivo [86]. Therefore, within the scope
of this study, we must first assess the BBB-crossing ability of the FLAP peptide as the
precursor to protecting the brain from these secondary injury cascades.
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To assess its effectiveness as a delivery vector, the peptide Fl-L57 was conjugated
to AIP, resulting in the conjugated peptide we termed FLAP. In Chapter 3, we described
the synthesis and characterization of the Fl-L57 and FLAP peptides. In Chapter 4, we
successfully demonstrated the ability of the peptide Fl-L57 to be taken up by BMVECs
and tested for cytotoxicity in three different brain cell types. To study its BBB-crossing
ability, it was then administered to mice- both uninjured and injured mice - with head
traumas induced by a fluid percussion model of injury. C57BL/6 mice were used in this
study. They are inbred to be genetically homogeneous, which lowers variability in
experiments.
Small peptides (<5 kDa), which include the peptides used in this study, that are
not bound to plasma proteins or taken up by tissue, are rapidly excreted via renal
filtration through the kidneys [120]. IN delivery was used to deliver peptides directly to
the brain to avoid losses through excretion. Figure 5-2 provides a snapshot of the
olfactory neuronal pathways and the intra- and extraneuronal mechanisms of drug
transport. Intranasally administered drugs may directly go into systemic circulation and
then enter the brain or enter the brain via the trigeminal or olfactory nerve systems [87].
The olfactory region of the nasal mucosa is a direct pathway to the CNS for drugs
delivered intranasally. It is divided into intra- and extraneuronal pathways. In the
intraneuronal pathway, the drug molecules are taken up via endocytosis, then through
axonal transport to reach the olfactory bulbs. In the extraneuronal pathway, the drug
molecules get transported in the gaps between the olfactory neurons in the olfactory
epithelium, eventually reaching the olfactory bulbs. The drug may later reach other parts
of the brain via diffusion by bulk flow mechanism and perivascular pumps [87].
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Figure 5-2: Nose-to-brain pathway for CNS drug delivery. From Mittal et al. [87].
5.2
5.2.1

Materials and Methods

Materials
The materials required for solid phase peptide synthesis are listed in section 4.3.1.

Additionally, to prepare the anesthesia cocktail, ketamine hydrochloride (Vedco),
xylazine (Vet One) and 0.9% saline (Teknova) were used. Poly(methyl methacrylate)
(Lang Dental) was used to make the dental acrylic for the injury hub installation and
agarose (VWR Chemicals) was used for the post-injury cap. For the cardiac perfusion
solutions, PBS (Gibco) was used, and 4% formalin solution was formulated from dibasic
sodium phosphate (Sigma), monobasic sodium phosphate (MP Biomedicals) and 37%
formaldehyde (Ward’s Science). For brain slicing, the brains were encased in low melting
point agarose (IBI Scientific). Antifade mounting media was formulated using n-propyl
gallate (MP Biomedicals), glycerol (Himedia) and Tris (VWR). 4',6-Diamidino-2-
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Phenylindole, Dilactate (DAPI, Roche Diagnostics) was used for cell nuclear labelling.
Neurotrace 530/615 red fluorescent Nissl stain was purchased from Life Technologies for
neuronal labelling. See Appendix for 4% formalin and antifade mounting media recipes.
5.2.2

Peptide Synthesis
L57 (FITC-Ahx-TWPKHFDKHTFYSILKLGKH-CONH2) and FLAP (FITC-

Ahx-TWPKHFDKHTFYSILKLGKH- (Beta-ala)-LARQLGVAA-CONH2) were
designed according to the design considerations explained in Section 3.4. These peptides
were custom-made by Biomatik (Cambridge, ON, Canada) (See Table 3-1: Amino acid
sequences of the peptides used in this study.). Both peptides were ordered at high purity
(> 95% purity), determined by high-performance liquid chromatography (HPLC), crucial
to perform in vivo BBB transport studies. Their original TFA counterions were also
exchanged to obtain acetate salts of the original peptide, with TFA < 1% to avoid assay
interference such as reduced pH and inhibition of cellular proliferation [115]. Peptide
molecular weight was confirmed by MALDI TOF mass spectrometry. See Table 5-1 for
peptide analytical information from the Certificate of Analysis.
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Table 5-1: Peptide characterization data for L57 and FLAP peptides.
Peptides

Sequences

Molecular
Weight
(Da)

Purity
(%)

TFA
(%)

Fl-L57

FITC-AhxTWPKHFDKHTFYSILKLGKHCONH2

2985.75

95.06

0.875

FLAP

FITC-AhxTWPKHFDKHTFYSILKLGKH- (Betaala)-LARQLGVAA-CONH2

3936.75

95.03

0.891

peptides were dissolved in 0.9% saline for the in vivo activity assays and kept at –20 °C in aliquots to avoid
repeated freeze-thaw cycles.
a All

5.2.3

Animal Preparation and Handling
All experimental procedures were conducted in conformity with the Louisiana

Tech University Institutional Animal Care and Use Committee-approved protocols for
the care and use of Laboratory Animals. Male and female C57BL/6NHsd wild-type mice
(8-16 weeks, 18-28 g) were purchased from The Jackson Laboratory and kept under a
constant environment (12 h light/ 12 h dark cycle). Food was allowed ad libitum. A
random number and combination of male and female mice were assigned into 5 treatment
groups: 1) Sham injury + vehicle (0.9% Saline), 2) TBI + vehicle (0.9% Saline), 3) TBI +
500 µM FLAP 45 min post-TBI. All treatment groups had at least 5 mice.
5.2.4

Injury Hub Surgery
Mice were weighed then sedated with 2% isoflurane mixed with air flowing at

500 ml/min using a Somnosuite digital vaporizer system (Kent Scientific Corporation,
Torrington, CT, USA). Immediately after sedation, the mice were given an
intraperitoneal administration of ketamine (10 mg/kg)/xylazine (1 mg/kg) (K/X) cocktail
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to induce anesthesia. The volume administered was 10% of body weight, followed by 1020% booster of the initial dose, if required. After the loss of toe-pinch reflexes was
confirmed, the fur on top of the head of the mouse was clipped and then the mouse was
placed atop a temperature-controlled heating pad and immobilized in a stereotactic frame.
The head was positioned using a nose bar and then secured with atraumatic ear bars. The
blink reflex is abolished after anesthesia therefore ophthalmic ointment was applied to
both eyes to prevent their drying. Then, the shaved skin was swabbed with
betadine followed by 91% IPA to prepare the surgical site. The surgery setup is shown in
Figure 5-3.

Figure 5-3: Setup of the injury hub surgery. The mouse is positioned in a stereotactic
frame and kept warm using an electrical heating pad. A microscope is used to view
the surgical area during surgery and ensure the cranial hole is properly positioned, and
a nose cone apparatus is fixed to the mouse nose to maintain a low % of air or
anesthesia if needed.
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A midline incision of the skin was made using a surgical scalpel and the exposed
cranium cleared of all connective tissue. A tiny (~0.5-mm height, 1.7 mm-wide) disc of
weed whacker line was glued to the skull on the sagittal suture, halfway between the
bregma and lambda coronal sutures to act as a guide for a handheld 3 mm trephine drill,
used to create a hole, as shown in Figure 5-4.

Figure 5-4: Craniectomy to expose the underlying dura mater for fluid percussion
injury. The portion of the skull for this surgery was drilled between the bregma
(anterior) and lambda (posterior) coronal sutures to ensure that the exposed cortex
would bilaterally (on both hemispheres) receive the injury uniformly. The dashed
circle outlines the craniectomy.
Throughout the craniectomy, utmost care was taken to prevent the puncture of the
dura. The craniectomy site was cleaned with saline and dried with a sterile cotton swab to
clear it of any blood and debris. If the dura was disrupted, as evidenced by excessive
blood loss, the mouse was sacrificed and replaced by another mouse. Every 15 min or so
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during the surgery, the depth of anesthesia was assessed via toe-pinch reflex and a small
volume of K/X solution was injected intraperitoneally if necessary.
An injury hub was fashioned from the female end of a 20 G hypodermic Luer
Lock needle hub and fixed over the injury site using cyanoacrylate glue. The hub was
further secured using Jet Denture dental acrylic/methyl methacrylate (Lang Dental),
which covered the surgical site around the injury hub. After the acrylic had dried, the hub
was filled with saline to keep the dura hydrated. The hub was then sealed with parafilm to
prevent leakage of the saline. Subsequently, the mouse was returned to its housing and a
heated pad was placed under the cage to aid in the recovery of the mouse. Mice were
monitored for about an hour post-injury.
5.2.5

Midline Fluid Percussion Injury (mFPI)
Animals were randomly selected to receive either mFPI or no injury depending on

the treatment group. The sham animals were subjected to all surgical procedures except
the delivery of the fluid injury pulse. The righting reflex time (RR) of the mouse was
recorded as an indicator of the severity of the injury. The RR is the duration of the time
from the delivery of the pulse to when the mouse rights on all fours from its supine
position. Mice subjected to mFPI were given a moderate injury (righting time of 5-13
minutes). Mice were also included if they had a RR time of greater than 13 minutes but
appeared relatively healthy after recovery, as assessed by rotarod and modified
neurological severity score (mNSS) scores in days post-injury. Severely injured mice,
such as mice that died post-injury were not included in the study.
After surgery, each mouse in the TBI treatment groups were given a mFPI after
they were fully mobile, ≥ 6 hours after surgery. Each mouse was anesthetized with 2%
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isoflurane using the Somnosuite system. The female injury hub of the mouse was then
filled with saline and attached to the male end of the FPI device (Custom Design and
Fabrication, Virginia Commonwealth University, VA) (See Figure 5-5) to create a tight
seal between the end of the tubing and the injury hub. Care was taken to ensure that the
hub was unobstructed to avoid the chances of a dampened and inadequate injury. This
was confirmed by the visualization of the underlying cortex through the saline in the
injury hub.
The device was primed several times to ensure a consistent fluid pulse pressure
and a smooth signal on the oscilloscope. The animal’s reflexes were checked and when a
response was seen, but before the animal fully gained consciousness, a single fluid injury
pulse (~20 ms) was given by releasing a pendulum hammer onto the piston of a fluidfilled cylinder. The injury hub was then detached from the device and the mouse was then
returned to its home cage (placed on a heating pad) in a supine position until it righted
itself and recovered from the injury. From the trace of the oscilloscope (Model TDS
1002, Tektronix), all the parameters were recorded to calculate the injury pressure. This
injury pressure for each mouse is monitored and noted to ensure consistency of the fluid
percussion injury across all injured mice. The RR times of the mice were recorded.
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Figure 5-5: Fluid Percussion Injury device injury system. The release of the
pendulum hammer set at a predetermined angle delivers an impact to the piston,
inducing a fluid pulse injury onto the exposed dura via the implanted injury hub. The
transducer at the end of the cylinder detects the force of the pulse, and the signal is
amplified then sent to the oscilloscope which shows it on the screen in mV. This
voltage can be converted to pressure (atm) to determine the force of the fluid
percussion injury delivered to the mouse brain.
After recovery, the mice were given an IN injection of the vehicle or peptide,
depending on the treatment group, within 45 minutes of the injury. Thereafter, the injury
hub was removed from the cranium under anesthesia and the brain inspected for uniform
herniation and to confirm that the dura was intact. Mice with injuries that showed
herniation were immediately euthanized and excluded from the study. 2% agarose gel
was prepared in advance using distilled water. The craniectomy hole was sealed using a
piece of this premade 2% agarose and cut to an area slightly wider than the hole. A
suitable amount of dental acrylic was added over the gel to cover the exposed cranium.
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The hardened acrylic forms a “cap” over the cranium to maintain sterility of the dura,
thus preventing infection to the brain.
5.2.6

Intranasal Administration of Peptide
For IN delivery of the vehicle (0.9% saline) or peptide (500 µM), the mouse was

first anesthetized under 2% isoflurane, and the following protocol was used to pipet 24 µl
of the solution into the nostrils using a 10 µl pipette tip. The mouse was kept in a reverse
Trendelenburg position and 6 µl of the solution was injected slowly into alternating left
and right nares to properly administer the solution. The second dosage was given 5
minutes after the first. Six µl has been shown to be the maximum volume applied to the
olfactory epithelium to prevent systemic leakage and aid the passage to the brain [88].
Mice were then returned to their home cage. This IN delivery was carried out first in
preliminary studies to assess the dosage of peptide required for adequate uptake which
was confirmed through visualization of localized fluorescence that was distinct from the
background. Fl-L57 and FLAP peptide concentrations of 500 µM and 1 mM were tested
to check for their BBB-penetrating ability via the nasal cavity. Once this concentration of
peptide was finalized, it was administered intranasally to injured mice in the treatment
group for a total of 6 days, i.e., 45 minutes after injury on Day 0, then around the same
time on 1-, 2-, 3-, 4- and 5-days post-injury (DPI).
5.2.7

Neurobehavioral Tests
Acute sensorimotor deficits and cognitive behavior were assessed using the

rotarod, mNSS, open field (OF), novel object recognition (NOR) and elevated plus maze
(EPM) tests. To minimize non-specific stress responses, mice were conditioned to human
interaction and touching during the rotarod training of the mice in the days before the
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injury. A timeline of the testing scheme is shown in Figure 5-6 below, with a full
summary in Table 5-2: Summary of neurobehavioral testing and drug administration
over the duration of the study.. Rotarod training was carried out 3 days prior to injury.
Rotarod and mNSS testing were done on Days 2, 5 and 7 after injury. All other tests,
including mNSS, OF, NOR and EPM, were performed at the acute (2-day) and subacute
(7-day) post-injury time points. All tests were run in the dark phase of the mouse sleep
cycle as mice are naturally nocturnal animals. For the OF, NOR and EPM tests, videos
were recorded using an overhead wide-angle web camera and analyzed offline.

Figure 5-6: Timeline of testing scheme.
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Table 5-2: Summary of neurobehavioral testing and drug administration over the
duration of the study.
Day

Test

-3, -2, -1

Rotarod training (Day -1 is
baseline)

0

Injury hub surgery and mFPI
(no mFPI for sham control
mouse)

1

Rotarod, mNSS, OF, NOR,
EPM1

2

Rotarod, mNSS, OF, NOR,
EPM

Experimental
mouse

Control mouse

IN 500 µM
FLAP (24 µL
total), given
45 min after
TBI,
thereafter, on
Days 1, 2, 3, 4
and 5 postinjury

IN saline (24 µL
total), given 45 min
after sham injury,
thereafter, on Days
1, 2, 3, 4 and 5
post-injury

Sacrifice and
brain
extraction

Sacrifice and brain
extraction

3
4
5

Rotarod, mNSS

6
7

Rotarod, mNSS, OF, NOR,
EPM

1Some,

not all mice had Day 1 testing as well. In those cases, Day 1 data were considered instead of Day 2 (1st
day tested).

5.2.7.1

Rotarod Test
The locomotor function of the mouse was assessed using a rotarod device, the

Touchscreen Rota Rod (Panlab Model # 76-0770, Harvard Apparatus) (See Figure 5-7:
Rotarod device setup. There are 5 lanes, with individual levers and timers, separated by
panels to ensure that the mice do not interfere with each other.). This 5-lane device with
individual lane timers can be used to test up to 5 mice at a time and can mechanically
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detect a mouse fall using levers. The latency to fall is an indicator of the severity of brain
injury and subsequent recovery in the days after injury [147].
For three consecutive days prior to surgery, the mice were trained on the rotarod
device (the acclimation phase). Three trials were conducted per day per mouse. The
rotarod test took place in 3 steps: 1) Stationary step: the mouse was placed on the
stationary rod and allowed to get accustomed to balancing on the stationary rod for at
least 30 seconds. Anytime the mouse fell, it was placed on the bar again until it could
successfully balance for 30 seconds; 2) Constant rotational step: The rotational speed was
set at 5 rpm without acceleration. The mouse was made to balance on the rod for at least
15 seconds while it was constantly rotating at 5 rpm. Just as in the first phase, anytime
the mouse fell, it was placed back on the rotating bar until it reached 15 seconds without
falling; 3) Acceleration step: The rotarod speed was adjusted to 0.2 rpm/s acceleration
and the lever raised up. The trial ended once the mouse fell onto the raised lever in its
lane and ended the lane timer. These 3 steps were repeated for the 2nd and 3rd trials, with
a 10-minute break in between the 2nd and 3rd trials where the mice were returned to their
home cages.
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Figure 5-7: Rotarod device setup. There are 5 lanes, with individual levers and
timers, separated by panels to ensure that the mice do not interfere with each other.
The latency to fall was recorded in minutes and seconds and the two longest trials
for the day were averaged to give the score time in seconds. The rotarod score for the day
before surgery was used as a baseline score. Due to a high variability in this score
between mice, the score was normalized on all days tested, to the baseline score using the
formula:
Normalized rotarod score = (Latency to fall (s) on Day x)/Latency to fall (s) on
Day -1), where x is the DPI.
5.2.7.2

Modified Neurological Severity Score
mNSS is the composite measure of neurological function graded on a scale of 0 to

8, using 8 different motor, sensory tests and reflex assessment tests. It is an excellent test
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to detect brain injury and subsequent recovery from brain injury [148]. Sham-injured
mice should possess no neurobehavioral deficits. This test was adapted from previous
experimental TBI models [149], [150]. The mouse was assigned a score of 0 for
completion of a task and 1 for failure to complete the task. The composite test comprised
of the following tests: 1) hindlimb flexion, 2) seeking behavior, 3) startle response, 4)
ability to traverse across elevated beams of 3 cm, 2 cm, and 1 cm widths sequentially and
5) balance on a 0.5 cm wide beam and 0.5 cm-wide rod. The mouse was given 1 minute
to cross 30 cm of the 3-, 2- and 1 cm beams towards a black box and had to balance on
the 0.5 cm rod and 0.5 cm beam for at least 3 seconds. The scores for the individual tests
for that day were added to obtain the mNSS score. Higher scores indicated greater
severity of the injury.
5.2.7.3

Open Field Test
OF and EPM tests were performed to evaluate the anxiety levels of the mice and

to analyze their exploratory behavior [151]. The OF test was carried out in a wooden
elevated box of 30 cm x 30 cm dimensions and height 25 cm (see Figure 5-8). Since the
C57BL/6J mouse strain is black, the inside walls and bottom of the box were painted
white to enable contrast between the mouse and the box. The mouse was placed in the
center of the open field and allowed to explore the box for 5 minutes before being
returned to its home cage. This test served as the acclimation step for the NOR test and
was always done immediately before the NOR test. Videos were analyzed using the
ImageOF (by Takao and Miyakawa) plugin for FIJI [141], [142].
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Figure 5-8: Overhead view of open field test setup and centroid trace. The OF recording
shows the open field with the mouse exploring it. In the representative trace on the right,
the path of the mouse can be seen as a centroid trace and used to analyze the amount of
time the object spends at the corners versus in the center of the box, i.e., middle 25% of the
field.
5.2.7.4

Novel Object Recognition Test
This test was carried out to assess the memory of the mice. Uninjured mice would

be able to recognize the novel object and discriminate between it and the old object.
Healthy mice, lacking memory deficits, tend to spend more time with a novel object than
one that is already familiar. The NOR is a low-stress test useful for detecting
neuropsychological changes after biological intervention [152]. The same box used in the
preceding OF test was used for this test as well.
First, two identical objects were placed in adjacent corners of the box. They were
the same shape, and the color was not important as mice cannot discriminate between
colors. Then the mouse was placed in the opposite side of the box facing the wall. The
mouse was allowed to explore the objects for 5 minutes before being returned to its home
cage. In the second half of the test, one of the objects was replaced by a new/novel object
and the mouse was again initially placed facing the opposite wall and allowed to explore
the objects for 5 minutes (See Figure 5-9). To prevent bias, the positions of the novel
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objects between tests were randomized. Exploration of an object included the mice
exploring the object by sniffing, touching, or climbing onto it. The percentage of time
spent exploring the novel object was quantified.
The discrimination index (DI) was calculated by:
DI = (time spent with novel object×100)/ (time spent with novel object + time
spent with identical object).

Figure 5-9: Novel object recognition test setup.
5.2.7.5

Elevated Plus Maze Test
The EPM test is a rodent test for anxiety-like responses and consists of 4 arms at

right angles to each other – 2 open and 2 closed (Figure 5-10) [153]. This test is based on
rodents' natural aversion to open spaces and their tendency to be thigmotaxic, i.e., they
prefer to stay in enclosed spaces. The open arms are aversive. The maze is an elevated
platform 50 cm above the ground and consists of 4 arms at right angles to each other with
2 opposing arms enclosed by 25 cm-high walls. The maze was painted white to provide
contrast to the black mice.
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The mouse was allowed to enter the maze in the same direction each time, i.e.
from an open arm, facing the center square of the maze, and allowed to explore the maze
for 5 minutes. Indices of open space-induced anxiety in mice were distance traveled, %
open arm stay time, and % entries into the open arms. These were calculated by the
ImageEP plugin for FIJI, developed by Komada et al. [154].

Figure 5-10: Elevated Plus Maze test setup and trace.
5.2.8

Behavioral Video Processing
To be readable in the FIJI software, the original videos were converted to

uncompressed Audio Video Interleave (AVI, .avi) files at 10 frames per second (fps)
without audio. Subsequently, these were converted to grayscale, shortened to exactly 300
s each, and cropped to the dimensions of the OF or EPM apparatus such that the visible
area was a square with equal length and breadth. The last frame of the video was edited to
be the background, i.e., without the mouse present. They were then saved as multi-TIFF
files to be readable by the plugins.
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5.2.9

Brain Perfusion and Post Sacrifice Brain Processing
Mice were sedated with isoflurane then deeply anesthetized with an

intraperitoneal injection of K/X solution (slightly over 10% of body weight). Noxious toe
pinches were given to confirm that the mice were in the plane of anesthesia. The mice
were then positioned on the surgery table in a supine position and taped to the table at the
forelimbs and tail. The thoracic cavity was exposed, and the aortic arch was nicked to
provide an outlet for blood drainage. Thereafter, using a 27G needle and a peristaltic
pump, the mouse was transcardially perfused through the left ventricle, first with ice-cold
1X PBS to clear the blood, and immediately after, ice-cold 4% formalin to fix the brain
tissue. After the brain was extracted from the skull, it was post-fixed in 4% formalin at 4
°C for around 15 hours then saturated in 30% sucrose solution at 4 °C to prepare it for
vibratome sectioning.
5.2.10

Vibratome Sectioning
The brain slices were sectioned using a vibratome EMS-5000 Oscillating Tissue

Slicer (Electron Microscopy Sciences, Hatfield, PA) (Figure 5-11A). The formalin-fixed,
sucrose-saturated brains were first wiped with a paper towel to remove excess solution,
then encased in 2% low-melt agarose in a plastic syringe (Figure 5-11B). The lowmelting agarose is essential to gently embed the brain in agarose gel without subjecting
the tissue to high temperatures. The brain was positioned in the syringe such that the
olfactory bulbs faced upwards. The agarose was then hardened using an ice bath.
Thereafter, the brain was sliced into two sections and cut to the desired orientation to
isolate the required area to be sectioned. Using cyanoacrylate, the agarose brain was
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glued onto the chilled mounting block and at a right angle to the block, with the olfactory
bulbs facing upwards (Figure 5-11C).
The block was then placed inside the mounting apparatus then screwed inside the
buffer tray and slid into the tray holder of the vibratome. Ice-cold PBS was poured into
the buffer tray, covering the block fully. Using appropriate oscillation and advance speed
settings, 60 µm tissue slices were obtained and collected in a 48-well plate with PBS. If
not mounted within a week, cryopreservative was used for long-term storage (See
Appendix A for recipe). Four consecutive slices were collected in each well.

Figure 5-11: Front view of EMS-5000 setup and agarose embedding of brain. A. The
EMS-5000 (OTS-5000) vibratome. B. The agarose-embedding of the fixed brain in 2%
low-melt agarose. C. The positioning of the mounting block in the buffer tray that was
filled with ice-cold PBS later.
5.2.11

Nissl Staining of Slices
Associated with the rough endoplasmic reticulum in neuronal perikarya and

dendrites, the Nissl substance is a physiological marker that redistributes within the cell
body in injured or regenerating neurons. NeuroTrace 530/615 red fluorescent Nissl stain
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(Invitrogen™) was used to stain the Nissl bodies in fixed tissue in normal and injured
brains. The purpose of Nissl staining was to compare neurons from injured and uninjured
mice from the same brain regions and identify cell morphologies characteristic of
secondary injury in TBI such as varicosities and terminal bulbs.
The stain was first diluted 200-fold in PBS. Approximately 200 µL of the diluted
stain was added to the slide, so that the sections were covered, and incubated for 20
minutes. Afterwards, the sections were washed twice in PBS for 5 minutes. Then the
stain was removed and washed for 10 min in PBS plus 0.1% Triton X–100. The sections
were washed again for 2 hours at room temperature or overnight at 4 °C in PBS.
The antifade media was pipetted onto the slide then the sections were covered
with a coverslip and imaged using the Leica microscope with a Cy3 filter cube (excitation
545/30, emission 610/75).
5.2.12

Slice Preparation and Imaging
To stain the nuclei of the cells, DAPI solution was pipetted to cover each slice and

then the slices incubated for 10 min at room temperature. It was pipetted off and then the
slices were washed thrice with PBS.
To reduce background fluorescence while imaging, optical clearing of the slices
was first carried out. This was done by successively saturating the slices with 37.5%,
75% and 90% glycerol solutions. After each glycerol solution, the slices were
equilibrated with gentle mixing on a rotary shaker at 4 °C. Subsequently, the next
solution was added, and the equilibration was repeated until the slices were saturated in a
90% glycerol solution.
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The brain slices were arranged on the slide in rostral-to-caudal order. Coronal
slices from different regions of the brain (except for the cerebellum) were mounted, to
check for peptide uptake throughout the brain. Since we were focused on checking for
peptide uptake in the cortex, non-cortical regions such as the cerebellum were not
sliced/mounted. Antifade media was pipetted to cover the slices, and then the coverslip
was placed over the media, taking care to avoid air bubbles on the slices. The excess
media around the edges of the coverslip was wiped off, then they were sealed with clear
nail polish. The slides were finally stored in a slide box until imaging.
Images were taken with either the Olympus BX51 or Leica DMI 6000B
fluorescence microscopes using the phase contrast, GFP filter (to image the FITC
peptides) (Olympus: 480/20 nm excitation, 510LP nm emission; Leica: 470 nm
excitation, 530 nm emission) and DAPI filter (Olympus: 365/10 nm excitation, 420LP
nm emission; Leica: 358 nm excitation, 461 nm emission). The images are taken in order
of decreasing wavelength, saving DAPI imaging for the end. For each microscope,
images of multiple regions of the same slice were taken at consistent settings, such as
those for exposure and light intensity.
5.2.13

Statistical Analysis
Statistical comparisons for the cellular uptake assay were performed using

repeated measures ANOVA as we measured the same test subjects over time. with
Tukey’s (comparisons between groups) for the fluorescence intensity data and Dunnett’s
(compared to control) post hoc correction for the cytotoxicity assay. For comparisons
between two groups, two-tailed t-tests were performed. All statistical tests were
performed using GraphPad Prism version 8.3.0 for Windows (GraphPad Software, San
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Diego, California USA, www.graphpad.com). Results were considered statistically
significant when p < 0.05. Values are represented as mean ± SEM of n mice for each
treatment condition.
5.3
5.3.1

Results

Preliminary Studies of Peptide Uptake
In preliminary studies using uninjured mice, the two peptides Fl-L57 (carrier

peptide) and FLAP (potential anti-inflammatory therapeutic) were delivered intranasally.
The two objectives of the study were to attain the IN concentration of peptide needed for
sufficient localization in the brain, leading to a strong fluorescent signal distinguishable
from the background fluorescence of the brain tissue, and to attain the biodistribution of
these peptides in the mouse brain.
First, after the IN delivery of peptides, an incubation period of 3 hours was
allowed before mouse sacrifice. No neurobehavioral tests were conducted in this phase as
the purpose here was to study the stated objectives without assessing potential therapeutic
effects on locomotor function, memory loss and recovery after injury. The Olympus
fluorescence microscope was used to image 60-µm slices in phase contrast and
fluorescence filters. DAPI images were not taken in this preliminary study.
Representative images of the olfactory bulb (OB) are shown in Figure 5-12 and of the
rostral forebrain in Figure 5-13.
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Figure 5-12: Fluorescence imaging of brain slices in the preliminary study. The
vehicle or peptide was injected intranasally and then the mouse was sacrificed 3 hours
later, and the brain harvested and fixed. Representative images of fluorescence in the
olfactory bulb taken using the GFP filter are shown in panels A, C, E, and phase
contrast images are in panels B, D and F. Images in panels A-E were taken with a 10X
objective and in panels G-H with a 20X objective.

91

Figure 5-13: Fluorescence imaging of brain slices in the preliminary study. The
vehicle or peptide was injected intranasally and then the mouse was sacrificed 3
hours later, and the brain harvested and fixed. Representative images of
fluorescence in the rostral forebrain taken using the GFP filter are shown in panels
A, C, E, and phase contrast images are panels B, D and F. All images were taken
with a 10X objective.
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The images obtained from the OB of peptide-treated mice showed large punctate
staining of the tissue in both Fl-L57 and FLAP peptides, in contrast to the OB in the
vehicle-treated mice. The staining was more prominent for the Fl-L57 peptide than the
FLAP peptide. Two concentrations (500 µM and 1 mM) were tested for each peptide,
with the characteristic pattern of staining observed for both peptides. This staining was
missing from the vehicle-treated brains. Images of the rostral forebrain slices did not
yield visible differences between the treated and untreated mice. For all subsequent
experiments, i.e., the 7-day TBI trials of the TBI study, 500 µM FLAP peptide was
administered to the treated mice to observe the effect of its anti-inflammatory peptide
segment on the recovery of the mice after TBI. We hypothesized that the mFPI would
induce leakiness of the BBB, facilitating better transcytosis of the FLAP peptide across
the BBB and thus better biodistribution of the peptide in the brains of TBI-injured,
treated mice than uninjured, treated mice.
5.3.2

Severity of TBI Injury
TBI-injured (n=13) mice received moderate mFPI injuries. The animals included

in the data analysis were further divided into FLAP-treated (n=5) and vehicle treated
(n=5) mice. The sham mice (n=5) received no injury but went through all procedures that
the TBI-injured mice were subjected to, with the exception that the hammer of the FPI
device was not allowed to hit the piston. The degree of severity of the injuries were
characterized by 3 parameters: RR time, mFPI pressure and mNSS.
5.3.3

Righting Response
Moderately injured mice (n=12) which showed RR times between 5 and 13 min

were included in this study. Mice which received mild injuries had RR times of less than
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5 min (n=4) were excluded. Additionally, mice were included if they had an RR time of
13-17 min but appeared relatively healthy after recovery, as assessed by rotarod and
mNSS scores later in days post-injury. Mice with severe injuries characterized by
immediate death after injury or RR times beyond 18 minutes (n=7), usually died postinjury and were sacrificed and therefore not included in this study. The data are shown in
Figure 5-14 as mean ± SEM. The sham group did not receive injuries therefore righted
instantly. The two TBI groups had similar average righting times: for the TBI + vehicle
group, mean RR time was 594 s, i.e., 9.9 min, and for the TBI + FLAP group, it was 553
s, i.e., 9.2 min.

Righting Times
800

Righting time (s)

700
600
500
400
300
200
100
0

Sham + vehicle

TBI + vehicle

TBI + FLAP

Treatment groups

Figure 5-14: Average righting response times (s) for the three treatment groups. Data
is represented as mean ± SEM. Treatment groups: sham mice (n=5), FLAP-treated
(n=5), vehicle treated (n=5) mice.
5.3.4

mFPI Impact Pressure
The fluid pulse pressure ranged from 2.8-3.5 atm.
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5.3.5

Neurological Severity Score
In this experimental model of TBI, the mNSS score was used as a composite

assessment indicative of neurobehavioral dysfunction of the mice. We expected that the
injured mice would have higher mNSS scores than the sham mice, indicative of a higher
degree of acute neurological deficits. As seen in Figure 5-15A, on Day 2, the mNSS
scores aligned with our expectations, with both injured groups having significantly higher
mNSS scores than the control group. This indicated that the TBI + vehicle group (H(2)
=10.44, p=0.0108) as well as TBI + FLAP group (H(2) =10.44, p=0.0076) received
significant injuries, enough to induce neurological deficits and the onset of secondary
brain damage. On Days 5 and 7, the mNSS scores were similar for all groups, indicating
the resolution of neurological impairment. Figure 5-15B shows the trend of NSS scores
between Day 1 and Day 7 for all groups. The sham group showed no deficits from Day 1
to Day 7. In contrast, the vehicle and peptide treatment groups had marked, identical
decreases in mSS by Day 7 (F(2)=9.100, p=0.0424).
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Figure 5-15: Modified neurological severity scores at Days 1, 5 and 7. A. NSS scores
of the treatment groups at each DPI. B. NSS scores of each group between Day 1 and
Day 7 DPI. Statistical analysis was performed using ANOVA (Kruskal-Wallis) with
the Dunn's multiple comparisons test comparing the injured groups to the sham control
group at each DPI. Data is represented as mean mNSS ± SEM. (*p<0.05, **p<0.01).
Treatment groups: sham mice (n=5), FLAP-treated (n=5), vehicle treated (n=5) mice.
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5.3.6

Rotarod Score
Sensorimotor skills were assessed on DPI 1, 5 and 7 together with NSS tests on

the same days. To account for inter-animal variability, the time of latency to fall was
normalized to baseline values (Day -1) and represented in Figure 5-16. For data analysis,
I conducted two-way repeated-measures ANOVA with post-hoc analysis by Fisher's
LSD. As expected on Day 1, the injured groups demonstrated a lower time of latency to
fall, consistent with the motor deficits noted in the NSS tests on the same day. However,
no significant differences in the fall times were found for the injured groups compared to
the sham group with no injury. The main effect of time was significant (F (1.925, 26.95)
= 3.953; p=0.0326). There was no interaction of the treatment and time. By Day 7, the
normalized scores increased from baseline for all groups, however, the vehicle-treated
group exhibited an increase in the scores from Day 1 to Day 7. This is indicative of an
expected learning curve. Overall, the TBI and treatment appeared to have no significant
effect on the latency to fall.
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Figure 5-16: Normalized accelerating rotarod scores showing latency to fall (s) at
Days 1, 5 and 7 DPI. Statistical analysis was performed using Two-way repeatedmeasures ANOVA. No significant differences were found between treatment groups.
Data is represented as mean normalized rotarod score ± SEM. Treatment groups: sham
mice (n=5), FLAP-treated (n=5), vehicle treated (n=5) mice.
5.3.7

Behavioral Testing

5.3.7.1

Open Field Test
The OF test was used in conjunction with the EPM test to assess the effect of the

treatment on the anxiety of the mouse and to evaluate exploratory behavior. Three
parameters were analyzed by paired t-tests at each time point: total distance (cm) (see
Figure 5-17A), total center time (s) (see Figure 5-17B) and moving speed (cm/s) (see
Figure 5-17C). No statistically significant differences were found between the injured
and uninjured groups. Additionally, by Day 7, the data looked similar to Day 1,
independent of treatment. The sham as well as vehicle- and peptide-treated mice spent
statistically similar amounts of time in the center zones, travelling similar distances in
total and at similar moving speeds.
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Figure 5-17: Open Field test at Days 2 and 7 post-injury. A. The total distance (cm) traversed by
the mouse in the open field. B. The total time spent by the mouse in the center (middle 25% of
area of the field (s). C. Moving speed (cm/s) of the mouse around the arena. Statistical analysis
was performed using two-way repeated-measures ANOVA to compare the injured groups to the
sham group, to account for the repeated testing of the mice on Day 2 and Day 7. No significant
differences were found between treatment groups. Data is represented as mean normalized
rotarod score ± SEM. Treatment groups: sham mice (n=5), FLAP-treated (n=5), vehicle treated
(n=5) mice.
5.3.7.2
Novel Object Recognition
The NOR test was done to study differences between the groups for the
preference of the novel object over the familiar object. This difference was characterized
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as the DI. If the DI was above 0.5, that meant the mice preferred the novel object over the
familiar object. As seen in Figure 5-18, The TBI-peptide group showed a trend towards
more time with the novel object compared to the sham and TBI-vehicle group by Day 7,
but the trend was not statistically significant.

Figure 5-18: Novel object recognition test results at Days 2 and 7 post-injury.
Statistical analysis was performed using two-way repeated-measures ANOVA. No
significant differences were found between treatment groups. Data is represented as
mean DI ± SEM. Treatment groups: sham mice (n=5), FLAP-treated (n=5), vehicle
treated (n=5) mice.
5.3.7.3

Elevated Plus Maze
The EPM test was performed on DPI 2 and 7 as a measure of anxiety levels of the

mice. Three parameters were measured: the total distance (cm) traversed by the mouse in
the EPM maze (see Figure 5-19A), % of the total time the mouse spent on the open arms
of the maze (see Figure 5-19B) and the % of open arm entries of the total number of
entries from the center square (see Figure 5-19C). Healthy, uninjured mice are relatively
averse to open spaces therefore usually do not exhibit a tendency to frequent the open
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arms and spend most of their time in the closed arms. The total distance traversed by the
mice in all groups appears to increase over time from Day 2, though not significantly
higher by Day 7. The vehicle treated TBI mice also appear to have a higher % open arm
stay time, indicating that the TBI has a possible effect, albeit not statistically significant,
on the anxiety levels of the mice. This effect diminished over time, and the Day 7 data
supported that the mice anxiety levels were on par with both sham and peptide treated
TBI mice by then. This observation is further supported by the number of times the mice
entered the open arm, calculated in terms of % of open arm entries, which decreased for
all groups from Day 2 to Day 7. There were no statistically significant differences
between groups tested on the same day or across days, indicating that the TBI did not
have a significantly marked effect on the anxiety levels of the mice.
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Figure 5-19: Elevated Plus Maze test at Days 2 and 7 post-injury. A. The total distance (cm)
traversed by the mouse in the EPM maze. B. % of the total time the mouse spent on the open
arms of the maze. C. % of open arm entries from the center square. Statistical analysis was
performed using one-way ANOVA for groups tested on the same day and paired t-tests across
days to account for the repeated testing of the mice on Days 2 and 7. Data is represented as mean
score ± SEM.
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5.3.8

Slicing and Fluorescent Imaging of Mouse Brains in the TBI Study
In the TBI study, the brains were post-fixed in formalin overnight on Day 7 then

saturated with 30% sucrose the next day. This saturation can serve the dual purpose of a)
preparing the brain for flash-freezing (using liquid nitrogen) to prepare it for slicing using
a cryotome, also, b) storing the brain until agarose embedding, in the case of slicing with
a vibratome. The vibratome sections were obtained in the rostral to caudal order, starting
with the olfactory bulbs. Prior to the TBI study, our preliminary results showed possible
localization of the peptide in the olfactory bulbs of the brain, therefore we focused on
those sections but also imaged the other parts of the brain, excluding the cerebellum.
Representative images from TBI-treated mice (vehicle and FLAP-treated groups) are
showed in Figure 5-20.
After 6 days of treatment, no significant localization of the FLAP peptide
throughout the brain was observed, as expected. The punctate staining for the treated
brain was visible and no such staining was observed in the control brain, in the OB
region.
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Figure 5-20: Fluorescence imaging of brain slices in the preliminary TBI study. The
vehicle or peptide was injected intranasally from Day 0 to Day 5 post-injury and then
the mouse was sacrificed on Day 7. The formalin-fixed brains were then sectioned,
stained with DAPI, and imaged using a fluorescence microscope. The first (A-C) and
third rows (G-I) represent the “vehicle” (TBI-injured, vehicle-treated) group, and the
second (D-F) and fourth rows (J-L) represent the “FLAP” (TBI-injured, FLAPtreated) group. Representative images of fluorescence taken using the GFP filter are
shown in panels A and D (Olfactory bulb), and G and J (rostral forebrain). Images in
the middle column (B, E, H and K) represent the fluorescence images merged with the
DAPI images, for the respective areas. Phase contrast images (C, F, I and L) are in the
last column of panels. All images were taken with the Leica microscope using a 10X
objective.
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5.4

Discussion

To facilitate imaging of the peptide distribution throughout the brain, mouse
brains were sliced and imaged. Our foremost purpose was to image the upper cortical
layers to check for peptide localization as the neural networks in those regions are most
impacted by the diffuse brain injury characteristic of the mFPI. We expected to see
increased peptide localization in the injured brains as compared to the uninjured brains
observed in the preliminary study, due to the leaky BBB morphology that is characteristic
of TBI in the acute phase of injury.
If a cryotome had been available, it would have been highly advantageous over a
microtome, as it can produce brain slices as thin as 5 microns. Even though all images
were taken at consistent settings, the lack of the ability to visualize a monolayer of cells,
obtainable with a cryotome, makes it difficult to assess the true biodistribution of the
peptide in the brain. On the other hand, the vibratome is easier to use and facilitates the
sectioning of tissue as thin as 20 microns. In our case, however, we were able to get the
slices down to 60-micron thickness. Thus, we were unable to obtain samples of the
desired thickness. The thick samples greatly impeded the verification of our results as the
slices were too thick to observe cellular localization of the peptides in distinct cell
monolayers. We also did not possess a confocal microscope to confirm our results. A
further examination of the brain slices via Nissl staining for neuronal damage was
restricted by the thickness of the brain slices and lack of necessary equipment, such as a
cryotome and confocal microscopy. The slices appeared hazy even when we used highmagnification objectives such as 20X and 40X. Furthermore, the neuronal pathology we
expected to see after TBI, such as varicosities and terminal bulbs, were not distinct.
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Even though the images of the OB panel in the brains of injured, treated mice
seem to have a higher fluorescence intensity than their respective controls, it is difficult
to quantify due to a lack of homogeneity in the distribution of the peptide. However, for
the rostral forebrain slices, the control brains appear to be brighter, signifying again the
presence of heterogeneous morphology throughout the slices.
The TBI-injured animals (both treated and untreated groups) had significant
neurological deficits following injury. The mNSS scores showed significant differences
between groups, with the TBI-vehicle treated animals having the highest average scores.
We expected the peptide to mitigate the secondary damage associated with TBI, but due
to the lack of localization in the brain cortex, it was difficult to determine if the peptide
had any effect at all on the behavior of the mice in the 7-day period. The neurobehavioral
tests such as OF, NOR and EPM did not display significant differences in functional
behavior among all groups, possibly due to the small sample sizes used in this study.
Another possible confounding factor could be the dependence of sex of the mice on their
behavior [155].
To ensure the observation of significant differences and a confirmation of
treatment of secondary injury, we would need to employ larger sample sizes. We would
also need more extensive studies which would involve testing the therapeutic effect of the
peptide on neuroinflammation such as to check if the pro-inflammatory factors were
significantly downregulated in the hippocampi of treated mice compared to the control
mice. It is possible that the employment of a short (7 days) period may have been
inadequate to observe the effect of the therapeutic on mouse behavior. In future work, a
longer time frame of testing (such as 2 weeks) would ensure the study of the implications
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of potential therapeutics on long-term/chronic neurological deterioration after TBI.
Moreover, to evaluate age-related differences in behavior, different age groups of mice
with sufficient sample numbers could be chosen.
To properly evaluate BBB-crossing of this FLAP peptide through this noninvasive IN route, we would need to develop better methods of BBB-penetration that
facilitates cortical uptake and localization, such as varying concentrations of the peptides,
time points and using different formulation ingredients such as buffers and
mucoadhesives. To the best of our ability and with our limited resources, we saw peptide
localization in the OB bulb of both peptide-treated groups, i.e., injured, and uninjured. As
a future objective, the AIP sequence alone could be compared to the FLAP sequence to
check whether the AIP localizes in the brain without being conjugated to a BBB-crossing
vector. Ultimately, our investigation can be focused on exploring the downregulation of
the inflammatory cascades in the OB with the AIP or FLAP to aid with synaptic and
axonal regeneration after TBI-associated secondary injury.

IN VITRO ELECTROCHEMICAL DETECTION OF REACTIVE
OXYGEN SPECIES IN ACTIVATED MACROPHAGES VIA
A PLATINUM MICROELECTRODE ARRAY
This dissertation chapter is based in full on the previously-published journal
article in MDPI Sensors, cited as “C. VM, R. JP, T. C, A. P, and P. S, “In Vitro
Electrochemical Detection of Hydrogen Peroxide in Activated Macrophages via a
Platinum Microelectrode Array,” Sensors (Basel), vol. 21, no. 16, Aug. 2021, doi:
10.3390/S21165607.” [13]. The work done in this chapter was undertaken as part of the
Master’s thesis research by Victor Carriere. Jr. JPR contributed significantly through the
planning and execution of experiments, data collection, analysis, and manuscript writing.
This journal article has been reproduced with permission from all the co-authors involved
in this study.
One of the hallmark observations of experimental TBI is the oxygen radicalinduced oxidative damage to the brain. Post-traumatic brain injury is perpetuated by the
inflammation cascade; the lipid peroxidation (LP) resulting from the oxidative attack of
highly reactive oxygen species (ROS) on polyunsaturated fatty acids in brain
microvascular and parenchymal compartments [156]. Peroxynitrite formed by ROS such
as superoxide (•O2-) and nitric oxide (•NO) impairs cerebral vascular function,
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culminating in poor circulation and ischemia. The end-processes of this damaging
cascade are DNA fragmentation and breakdown of the mitochondrial electron transport
system, ultimately inducing apoptosis/necrosis [157]. The search for a non-invasive ROS
assay to monitor TBI progression and possibly enable diagnosis of the injury level may
seem like a daunting task, but the first steps towards the development of such an assay
would require the in vitro testing of ROS-producing cells for proof-of-concept evaluation.
To that end, an electrochemical ROS detection system was developed and tested in a
murine macrophage cell line, RAW 264.7.
6.1

Abstract

Oxidative stress, an excess of endogenous or exogenous reactive oxygen species
(ROS) in the human body, is closely aligned with inflammatory responses. ROS such as
hydrogen peroxide (H2O2), superoxide, and radical hydroxyl ions serve essential
functions in fighting infection; however, chronic elevation of these species irreversibly
damages cellular components. Given the central role of inflammation in a variety of
diseases, including Alzheimer’s disease and rheumatoid arthritis, a low-cost,
extracellular, minimally invasive assay of H2O2 measurement is needed. This work
reports the use of a platinum microelectrode array (Pt MEA)-based ceramic probe to
detect time and concentration-dependent variations in H2O2 production by activated
RAW 264.7 macrophages. First, these cells were activated by lipopolysaccharide (LPS)
to induce oxidative stress. Chronoamperometry was then employed to detect the quantity
of H2O2 released by cells at various time intervals up to 48 h. The most stimulatory
concentration of LPS was identified. Further experiments assessed the anti-inflammatory
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effect of dexamethasone (Dex), a commonly prescribed steroid medication. As expected,
the probe detected significantly increased H2O2 production by LPS-doped macrophages,
subsequently diminishing the pro-inflammatory effect in LPS-doped cells treated with
Dex. These results strongly support the use of this probe as a minimally invasive, robust,
point-of-care test of inflammation, with a high potential for multiplexing in further
studies.
6.2

Introduction

Reactive oxygen species (ROS)—principally superoxide (•O2-), radical hydroxyl
ion (•OH), and nonradical hydrogen peroxide (H2O2)—are present in nearly all aerobic
cell types [158]. When reactive radicals such as superoxide and nitric oxide hybridize,
they form peroxynitrite (ONOO-), which is a highly reactive oxidizing agent, more toxic
than the parent species. Peroxynitrite (ONOO-) and nitric oxide (•NO) are types of
reactive nitrogen species (RNS), which, together with ROS, may transiently exceed the
capacity of the body to remove them—a condition known as oxidative stress . Oxidative
stress is associated with numerous adverse health effects [158]–[160]. At the cellular
level, these ill-effects include irreversible oxidation of DNA, lipids, and amino-acid side
chains (e.g., protein carbonylation) [158]. However, ROS/RNS species play a central role
in essential physiological functions, such as the activation of macrophages to deploy ROS
in fighting infection [161]. This ROS-mediated “respiratory burst” is a key component of
the inflammatory response necessary for the regulation of cell growth and survival.
Despite the short-term benefit of this immune response, chronic inflammation is
characteristic of diseases such as cancer, atherosclerosis, rheumatoid arthritis,
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Parkinson’s disease, and Alzheimer’s [158], [161]–[163]. Chronic inflammation involves
a state of prolonged oxidative stress in which the normal mechanisms of inflammatory
resolution are impaired or do not function, such as the recruitment of anti-inflammatory
M2 macrophages [164]. Chronically elevated levels of ROS, then, may have far-reaching
detrimental effects in the body [165].
Hydrogen peroxide is one of the primary redox signals in the body [159]. It is a
non-radical product of the superoxide dismutase SOD-catalyzed dismutation of
superoxide, which is produced continuously in mitochondria and elsewhere [166]. The
most prevalent sources of endogenous superoxide are the electron transport chain of
mitochondria, which generates superoxide radicals and occasionally hydrogen peroxide.
Superoxide is generated and released by the NADPH oxidase (NOX) complexes as
shown in Figure 6-1 [160]. Studies have shown that dual oxidase (DUOX) enzymes and
the isoform NOX4 can produce H2O2 directly [167].

Figure 6-1: Conversion of free oxygen to superoxide radical species and hydrogen peroxide
through the enzymes NOX and SOD.
Much of the oxidative damage caused by hydrogen peroxide occurs indirectly,
e.g., through the Fenton reaction in the presence of ferrous iron and the subsequent
production of hydroxyl radicals [168]. Elevated H2O2 levels are a hallmark of
inflammation and oxidative stress [162]. Since H2O2 is the most stable ROS in vivo, H2O2
is a suitable choice of biomarker in an assay of inflammation [169].
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Current methods to detect and quantify oxidative stress, including ROS and RNS
and their reactive intermediates, include spectroscopic methods, fluorescent-dependent
methods [159], [170], the use of chemiluminescent probes [171], [172],
spectrophotometric methods [173], chromatographic methods [174], and electrochemical
sensors [175]. Each of these methods suffer from limitations such as the quenching of
fluorescence when fluorescent probes or dyes are used and the inability of these dyes to
penetrate deeper layers of tissue. More recently, Vaneev et al. [176] reported in vitro and
in vivo electrochemical measurement of ROS using an intracellularly placed platinized
nanoelectrode. Although in vitro work appeared promising, the detection was somewhat
invasive, having to pierce the cellular membrane, possibly compromising membrane
integrity. This method also appeared to be impractical in the case of ROS detection in
tissues, where the thickness of the tissue sample would provide inaccurate results.
The Amplex Red reagent is commonly used as an extracellular indicator of H2O2
production. Amplex Red is oxidized by horseradish peroxidase (HRP) in the presence of
H2O2 to form resorufin, a fluorogenic molecule [160]. This assay is highly specific for
H2O2 and, because H2O2:resorufin stoichiometry is 1:1, may be used to quantify
extracellular H2O2 production [160]. However, similar to all fluorescent molecules,
resorufin is subject to photobleaching with the subsequent attenuation of fluorescence.
This tendency presents a practical problem in the design of an assay of inflammation.
The use of chronoamperometry in the detection of H2O2 and other ROS/RNS
released by a small population of RAW 264.7 cells in a Pt MEA-containing microfluidic
chamber has been demonstrated [177]. However, the intricacy of such a design may be of
limited utility in a medical laboratory.
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On the other hand, the ready availability of ceramic Pt MEA probes may permit
the development of a more rapid scalable assay of extracellular H2O2. Furthermore, the
ease of modifying the microelectrode surface allows for a wide range of multiplexed
applications demonstrated from our group. Hossain et al. report the fabrication of a
multiplexed glutamate/gamma-aminobutyric acid (GABA) Pt MEA probe via the
addition of glutamate oxidase (GlOX) and GABase to separate microelectrodes within
the same probe; this probe was used to detect ex vivo release of GABA in hippocampal
rat brain slices [178]. Scoggin et al. report the use of GlOX-modified Pt MEA probes in
vitro to detect glutamate uptake in astrocytes versus glioma cells [179].
In our study, we employ a similar approach to Vaneev [176] and Hossain and
Scoggin [178], [179] using a Pt MEA probe in an extracellular detection strategy. The
immediate goal of this project is the minimally invasive post hoc detection of stable
concentrations of H2O2 released by a large population of macrophages and accurately
detectable above baseline levels. Hence, real-time detection of H2O2 production by a
small population of cells, as by Varma et al. [180], was not attempted. Instead, H2O2
release was induced as follows: 1 × 105 RAW 264.7 cells were incubated with varying
concentrations of LPS for 6–48 h before testing for 4–8 min with the probe, to capture the
electrochemical signals over different time periods and durations of probing. Sies et al.
[181] reported the normal intracellular physiological H2O2 concentration as 1–10 nM in
human liver, with extracellular concentrations being 100-fold. As our study was based on
cell monolayer culture, our detection range planned to cover the oxidative eustress and
distress ranges of the RAW 264.7 cells, with the expectation that the level of cellular
complexity would be much lower in this study, enabling adequate detection.
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To assess the feasibility of the Pt MEA as an H2O2 assay, the following
hypotheses were investigated: (1) the probe will sense H2O2 over a physiologically
relevant linear range (1–10 µM), (2) RAW 264.7 cells will produce H2O2 in response to
LPS doping, (3) the probe will detect significantly more H2O2 in culture medium in LPSdoped samples than in untreated controls, (4) LPS-stimulated H2O2 production will be
greater at the physiologically relevant temperature of 37 °C than at 4 °C, (5)
dexamethasone, an anti-inflammatory steroid, will attenuate H2O2 production in LPSdoped samples, and (6) LPS doping and the operation of the probe will not adversely
affect cell viability.
6.3
6.3.1

Materials and Methods

Fabrication and Preparation of Pt MEA Probes
All Pt MEA probes were fabricated at the Center for Microelectrode Technology

(CenMeT, University of Kentucky, Lexington, KY, USA) in conjunction with Thin Film
Technology, Inc. (Buellton, CA, USA). Fabrication was performed as follows: a ceramic
wafer (0.005 ± 0.0005 in. thick) was cleaned with sulfuric acid and chromium trioxide,
rinsed with deionized water, and dried at 120 °C [182]. Photoresist was evenly spun over
the whole surface of the ceramic wafer. A mask was used to etch the design of the
microelectrode recording sites, bonding pads, and wires onto the photoresist [182]. Upon
development of the photoresist, this design was exposed. An adhesion layer of titanium
(500 Å), followed by the layer of platinum (1500 Å) that would comprise the Pt MEA,
was coated onto the printed circuit [182]. Each ceramic wafer contained 56
microelectrodes. Upon diamond cutting of the wafer into discrete probes, each new probe
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contained eight platinized, platinum microelectrodes (100 µM × 50 µM) in four pairs.
The recording site pairs are shown in Figure 6-2 and have 100 µm separation.

6.3.2

Cleaning

Figure 6-2: Details of the 8-TRK probe used in this project (CenMeT, University of
Kentucky, Lexington, KY, USA). Each recording site is 50 × 100 µm. The spacing between
recording site pairs is 1 mm, 1 mm, and 2 mm [55].
The probes were cleaned first in methanol and then electrochemically in acid. A
size-exclusion layer of m-phenylenediamine (mPD) that rejects larger sized molecules
was electrochemically coated over the Pt MEAs to mitigate the effect of interferents and
further improve selectivity. Firstly, the Pt MEA probe was immersed in 0.05 M sulfuric
acid in a two-electrode setup. In lieu of the Ag/AgCl reference electrode used in ROS
assays, the more robust saturated calomel electrode (SCE) was used. A Gamry Reference
600+ potentiostat (Gamry Instruments, Warminster, PA, USA) was used to cycle one Pt
microelectrode 15 times between −0.3 V and +1.0 V with a scan rate of 20 mV/s. Each of
the remaining microelectrodes was cycled in this manner. The purpose of this acid
cleaning is to increase H2O2 sensitivity via increasing the electrocatalytic sites by
electrochemically etching the Pt grain boundaries and significantly reducing the charge
transfer resistance of the Pt grains [183].
Secondly, the Pt MEA was immersed in a nitrogen-purged, 10 mM solution of
mPD in 1 M NaCl. The same Pt MEA/SCE two-electrode setup described above was
used, and each of the microelectrodes was continuously cycled between +0.2 V and +0.8
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V, with a scan rate of 50 mV/s, for 40 min to achieve a coating thickness of ~37 ± 2.4 nm
(mean ± SEM, n = 4). Upon completion of potential cycling, the probe was rinsed with
deionized water and allowed to air-dry overnight.
6.3.3

Cell Culture and Probe Conditioning
RAW 264.7 cells (American Type Cell Collection, murine macrophage cell line)

were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM; VWR) with 4.5 g/L
glucose, L-glutamine, and sodium pyruvate, supplemented with 10% FBS and 1%
penicillin/streptomycin. Cells were cultured in 75 cm2 cell culture flasks (CellStar; T-75)
and grown in a 37 °C, 5% CO2 incubator (VWR). Media was changed every 2–3 days or
as needed: flasks were checked daily for notable color changes in the media. A pinkishorange appearance indicated acidification by cellular waste products of the phenol red pH
indicator present in DMEM. When the cells reached 80% confluency, they were seeded
in 24-well plates at a density of 1 × 105 cells/mL (for other plate types, seeding density
was scaled up or down according to the surface area of the plate wells).
6.3.4

Treatment of Cells with Lipopolysaccharide or Dexamethasone
After 24 h, the confluency of the cells was assessed under the inverted light

microscope. When the cells were 50% confluent, they were doped with
lipopolysaccharides (LPS) and/or dexamethasone (Dex) and placed in the incubator.
RAW 264.7 cells were stimulated with varying concentrations of LPS (Enzo
LifeSciences, Farmingdale, NY, USA) derived from Escherichia coli strain EH100 (Ra
mutant). Cells were also treated with varying concentrations of Dex (Alfa Aesar,
Haverhill, MA, USA). Both reagents were added via one of two methods:
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6.3.4.1

Method 1
Beginning with stock solutions of LPS or Dex and diluting separately in complete

DMEM warmed to 37 °C, a 2X working solution of each desired final concentration was
prepared. After aspirating spent media from each well, cells received, e.g., for LPS-only
groups, 0.5 mL 2X LPS solution and 0.5 mL DMEM.
6.3.4.2

Method 2
Working solutions (10X) of each desired final concentration of LPS or Dex were

prepared in 1X phosphate buffered saline (PBS). 100 µL of media from each well was
aspirated and replaced with an equivalent volume of 10X LPS, 10X Dex, or PBS. Wells
receiving LPS and Dex had 200 µL media removed and replaced by 100 µL of each of
the respective solutions.
6.3.5

Setup and Use of the Probe

6.3.5.1

Calibration in the Presence of H2O2
As shown in Figure 6-3 and Figure 6-4, an 8-TRK probe was affixed to the head

stage, which was connected to the Fast Analytical Sensing Technology (FAST)
potentiostat/control box (FAST-16mkIII, Quanteon) and submerged in 10 mL DMEM in
a 20 mL beaker, as shown in Figure 6-3, to complete the calibration setup. A stirring hot
plate (Corning) and magnetic stir bar were also used to ensure continuous steady
transport of H2O2 to the Pt MEA surface. While the media was stirred at a constant rate,
amperometry was performed. When the slope of the current readout reached a
sufficiently flat baseline (<|2| pA/min), increasing volumes of a 2 mM solution of
stabilized H2O2 (Sigma) were aliquoted to the beaker, and the corresponding increases in
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current were noted. Sensitivity (pA/µM) was derived from the slope of the calibration
curve.

Figure 6-3: Experimental setup of the probe during calibration. The magnetic stirrer
ensured a continuous steady flow of H2O2 to the electrode surface.

Figure 6-4: Setup of probe during amperometry experiments (+0.7 V vs. Ag/AgCl
reference electrode). Data are recorded at a frequency of 10 Hz and displayed in real
time as current (nA) vs. time (s).
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Prior to each amperometry experiment, the probe was calibrated via the stepwise
addition of H2O2 to cell culture medium. Abnormally large baseline currents obtained
during calibration were assumed to reflect degradation of the mPD coating. Much
empirical evidence established that the selectivity of such probes was compromised; 100
pA was selected as the baseline current above which probes should be discarded and
replaced.
6.3.5.2

Detection of Extracellular H2O2
Each 24-well plate was removed from the incubator and partially immersed in a

37 °C water bath (VWR). The Pt MEA was secured to a manual micromanipulator
(World Precision Instruments), which was positioned such that the probe was inserted
into the culture medium and secured 5 mm above the bottom surface of the plate. Using
the mPD-coated platinum microelectrode array (Pt MEA) with the FAST-16mkIII
potentiostat in a two-electrode configuration, we performed chronoamperometry at an
applied potential of +0.7 V with reference to an Ag/AgCl electrode. Current
measurements were taken at a frequency of 10 Hz. The FAST system software
(Quanteon) was used in all chronoamperometry experiments.
As proof-of-concept for detection of H2O2 release, RAW 264.7 cells were
incubated at 37 °C, 5% CO2 until they reached ~50% confluency, then doped with 200 ng
or 500 ng LPS. After further incubation for 24 h under the same conditions, the cells were
probed.
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6.4
6.4.1

Results and Discussion

Calibration of the Probe in the Presence of H2O2
Calibration curves are shown in Figure 6-5; amperometry was performed in 10

mL of continuously stirred DMEM (+0.7 V voltage step versus Ag/AgCl; recording
frequency: 10 Hz).

Figure 6-5: Representative graph of probe calibration in the presence of H2O2. A.
Increasing volumes of 2 mM H2O2 were added at sixty-second intervals such that the
following final concentrations were reached: 0 µM, 0.31 µM, 1 µM, 2 µM, 4 µM, 8
µM, and 10 µM. B. A linear fit of the current detected at each calibration step yielded a
sensitivity of 6.743 pA/µM (R2 = 0.9979).
In the example calibration shown in Figure 6-5A, noise is seen at points of H2O2
addition (e.g., at 1980 s) and due to disturbances in the media (e.g., at 2030–2040 s).
However, this is a typical characteristic feature of the probe calibration curve and is
expected.
Care was taken to minimize background noise during testing. The analysis of
experimental data was automated in MATLAB. Briefly, random noise was filtered via the
averaging of detected current at fifty evenly spaced time points across the last minute of
testing. Additionally, the use of cell-free controls in each experiment helped ensure that
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noise of a longer duration would not artifactually increase the current and hamper
accurate measurement.
6.4.2

Optimization of LPS and H2O2 Doping Protocol
To test the ability of the probe to detect H2O2 released by LPS-doped activated

macrophages, 1 × 105 cells/well were seeded in 24-well plates and incubated for 24 h.
When the cells were 50% confluent, they were doped with 200 ng/mL or 500 ng/mL LPS
according to Method 1 (see Method 1), incubated for 24 h, and tested. The following
controls were included in this experiment. Negative controls used media with cells
(media/cells) only (no doping of LPS). One positive control used media/cells with H2O2
(2 min); 2 µL of stock H2O2 was aliquoted two minutes before testing into wells
containing media and cells (final concentration in well: 4 µM). A second positive control
used media/cells with H2O2 (24 h); 2 µL of stock H2O2 was aliquoted 24 h before testing
(i.e., at the time of LPS addition) to wells containing media and cells. This control was
included to ensure that a known concentration of exogenous H2O2 would remain stable
enough in solution to be detected by the probe. The difference in signal between both
positive controls was used to assess the stability of extracellular H2O2 released by LPSdoped cells.
To assess the efficacy of this protocol, the following experiment was performed.
RAW 264.7 cells were seeded in 24-well plates, as above, incubated for 24 h, and doped
with 200 ng/mL or 500 ng/mL LPS. The resulting data showed an enhanced H2O2generating response in LPS-doped cells, with significantly elevated H2O2 production in
both 200 ng/mL (p = 0.039) and 500 ng/mL-treated (p = 0.021) cells (see Figure 6-6).
H2O2 produced was not significantly different between the two groups.
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Figure 6-6: Effect of lipopolysaccharides on hydrogen peroxide production in
RAW 264.7 cells. Cells were seeded in 24-well cell culture plates at a density of 1 ×
105 cells/well. Upon reaching ~50% confluency, treated cells were spiked with LPS
in two concentrations (200 ng/mL and 500 ng/mL, in triplicate), then incubated for
24 h. After calibration of the Pt-MEA against H2O2 in complete cell culture medium
(DMEM), amperometry was performed in each well for four minutes with a
potential step of +0.7 V against an Ag/AgCl reference electrode. The sensitivity
obtained during calibration (9.975 pA/µM; R2 = 0.9995) was used to translate
current for each experimental condition to normalized H2O2 concentration (µM).
Data shown correspond to Electrode 1 (E1), the electrode nearest the cells. Oneway ANOVA (n = 5, p = 0.002) was performed to assess the significance of
differences among all group mean concentrations, followed by the Tukey–Kramer
test to assess pairwise significant differences (n = 5, * p < 0.05).
H2O2 showed apparent persistence in the 24-hour positive control: currents
generated (i.e., H2O2 detected) at E1 in the H2O2 (2 min) and H2O2 (24 h) groups were
not significantly different (p = 0.99998). The normalized H2O2 concentrations in both
positive controls were ~6 µM—consistent with the expected ~4 µM increase above
average H2O2 concentration in the cells-only negative control (1.88 ± 0.30 µM).
Given the possibility of macrophages metabolizing external H2O2 to
concentrations below the LOD of the probe [184], the similar signals obtained in both
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H2O2-positive controls indicate a robust ability to detect H2O2 incubated for long periods
with live cells. This result extended to LPS-doped cells as well. Taken together, these two
results validate the hypothesis that stable extracellular concentrations of LPS-induced
H2O2 may be detected in RAW cells via the probe.
6.4.2.1

LPS Dosage Concentration for H2O2 Detection
Figure 6-7 shows the optimal LPS concentration for extracellular H2O2

production; therefore, only two selected concentrations of LPS were included in the next
experiment. RAW 264.7 cells were seeded in 24-well plates as above and doped with
LPS in the following (final) concentrations: 200 ng/mL, 500 ng/mL, 800 ng/mL, and
1000 ng/mL. The cells were incubated for 12 or 24 h before testing. H2O2 production in
RAW 264.7 cells showed no significant LPS dose dependence (Figure 6-8), implying
that the range of LPS concentrations assayed, 200 ng/mL–1 µg/mL, is saturating yet
sublethal. Extracellular H2O2 production was more pronounced at the two lower
concentrations of LPS (Figure 6-7). The apparent stability of extracellular H2O2 was
further supported by this experiment: between 12 h and 24 h, only the highest dosage of
LPS (1 µg/mL) showed any statistically significant reduction in H2O2 detected by the
probe, whereas the lower concentrations remained relatively stable over this period.
Given the toxicity of LPS and the potential concomitant reduction in cell viability [185],
the lowest dose, 200 ng/mL, was selected as the best concentration for further study.
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Figure 6-7: Effect of lipopolysaccharides concentration on hydrogen peroxide
production in RAW 264.7 cells. Four concentrations of H2O2 (200 ng/mL, 500 ng/mL,
800 ng/mL, and 1000 ng/mL) were added to cells in triplicate. Cells were incubated for
12 or 24 h. The sensitivity obtained was 4.10 pA/µM (R2 = 0.9995). Data shown to
correspond to Electrode 1 (E1), the microelectrode nearest the cells. One-way ANOVA
(n = 14, p < 0.001) and the Tukey–Kramer test (n = 14, * p < 0.05, ** p < 0.001) were
used to assess statistical significance.

Figure 6-8: Effect of incubation time on H2O2 production in RAW 264.7 cells. An
amount of 200 ng/mL LPS was added to cells plated in triplicate in 24-well plates
(seeding density: 1 × 105 cells/mL). Cells were incubated for 6, 12, 24, or 48 h. Probe
sensitivity: 11.0 pA/µM (R2 = 0.9997). One-way ANOVA (n = 21, p < 0.001) and the
Tukey–Kramer test (n = 21, ** p < 0.001) were used to assess statistical significance.
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6.4.3

Incubation Time Study
Figure 6-8 summarizes time studies that were performed to discern the effect of

incubation time on H2O2 production. The optimal LPS concentration of 200 ng/mL was
used. RAW 264.7 cells were seeded in 24-well plates as described previously, then doped
with 200 ng/mL LPS and incubated for 6, 12, 24, or 48 h.
At each of the four time points, H2O2 was significantly elevated in LPS-treated
cells versus cell-only controls (p < 0.001). Somewhat unexpectedly, the LPS-stimulated
H2O2 detected was not statistically different across the four time points. This prolonged
stability indicated that 200 ng/mL LPS produced a stable, saturating concentration of
extracellular H2O2. While comparing these incubation timepoints, LPS stimulation of the
cells at all these timepoints exhibits statistically similar [H2O2] release. Thus, selecting an
optimal LPS incubation time was somewhat arbitrary; therefore, one or more of these
incubation timepoints were chosen for subsequent experiments.
6.4.4

Incubation Temperature Study
The inflammatory response depends on metabolically functioning cells, which

must initiate a host of synthetic and transport processes. In order to determine that the
H2O2 measured is due to cellular processes, LPS-doped cells were incubated at 4 °C. The
functioning of mammalian cells in vitro depends strongly on incubation temperature, it
was expected that H2O2 production in LPS-doped RAW cells incubated at 4 °C would be
near zero.
To assess the effect of reduced incubation temperature on H2O2 production, RAW
264.7 cells were seeded in 24-well plates as described above. All plates were initially
incubated at 37 °C, 5% CO2 to ensure the cells could adhere and proliferate. After doping
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the cells with 200 ng/mL LPS, cells were incubated at either 4 °C or 37 °C for 48 h.
Subsequent testing with the ROS probe revealed the expected lack of extracellular H2O2
produced by 4 °C-incubated cells as shown in Figure 6-9.

Figure 6-9: Effect of reduced incubation temperature on H2O2 production in RAW
264.7 cells. LPS-doped cells received 200 ng/mL in each well. Cells were incubated for
48 h at 4 °C or 37 °C (5% CO2) following addition of LPS. Probe sensitivity: 11.0
pA/µM; R2 = 0.9997. One-way ANOVA (n = 8, p < 0.001) and the Tukey–Kramer test
(n = 14, * p < 0.05, ** p < 0.001) were used to assess statistical significance.
H2O2 was significantly elevated when LPS-doped cells were incubated at 37 °C,
whereas little or no H2O2 were detected for cells incubated at 4°C, thus supporting the
metabolic energy dependence of H2O2 production in LPS-activated macrophages. An
important consideration to note is the possibility of the cells incubated at 4 °C being dead
at 48 h, so in future studies, a shorter timeframe could be used for this temperaturedependence study.
6.4.5

Effect of Dexamethasone on H2O2 Production
Figure 6-10 shows the effect of an anti-inflammatory drug on H2O2 production. It

was expected that the anti-inflammatory glucocorticoid dexamethasone (Dex) would
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counter the action of LPS, thus reducing cumulative H2O2 production in LPS-doped
RAW 264.7 cells [186]. To assess the effect of treating cells with Dex in conjunction
with LPS, cells were treated with 200 ng/mL LPS and either 200 nM or 400 nM Dex,
then incubated for 6, 12, 24, or 48 h.

Figure 6-10: Effect of dexamethasone on H2O2 production in RAW 264.7 cells. Cells
received 200 ng/mL LPS and/or 200 nM or 400 nM Dex in each well. Cells were
incubated for 6, 12, 24, or 48 h following addition of LPS and/or Dex. Probe
sensitivity: 11.0 pA/µM; R2 = 0.9997. One-way ANOVA (n = 14, p < 0.001) and the
Tukey–Kramer test (n = 14, * p < 0.05, ** p < 0.001) were used to assess statistical
significance.
At each of the four time points, cells treated with LPS and Dex (200 nM and 400
nM) produced significantly more H2O2 than cell-only controls (p < 0.001). The H2O2
production effect was mitigated by Dex at three time points: at 6, 12, and 24 h after
treatment, LPS + Dex groups produced significantly less H2O2 than the LPS-only positive
control (6 h and 12 h: p < 0.05; 24 h: p < 0.001). Between 6 and 24 h, these data appear
to show the anti-inflammatory action of Dex being gradually outpaced by LPS-stimulated
H2O2 production. Yet, 48 h after treatment, the anti-inflammatory, ROS-suppressive
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effect was strongest (p < 0.001). Unexpectedly, Dex alone stimulated significant H2O2
production (p < 0.05) at 48 h. This seeming paradox should be investigated further.
Despite the imperfect trend in the data, these results support that the probe may be used
as an extracellular assay not just of H2O2, but of inflammation in general.
6.4.6

Viability Assay of LPS-Doped and ROS-Probed Cells
In order to assess the viability of cells after LPS stimulation, an MTT assay kit

(Promokine) was used. Cells were cultured in 96-well plates and subjected to one of the
following conditions: (1) negative control, (2) 200 ng/mL LPS, (3) 500 ng/mL LPS, (4)
exposure to the ROS probe (+0.7 V against Ag/AgCl) for 5 min, (5) exposure to the ROS
probe (+0.3 V against Ag/AgCl) for 5 min.
With both 200 ng/mL and 500 ng/mL LPS, RAW 264.7 cells exhibited viability
slightly greater than 100% (p > 0.05): LPS appears to encourage proliferation at these
doses as shown in Figure 6-11. This result agrees with a phenomenon observed in the
inverted microscope; after incubation with LPS in 24-well plates, these cells often
appeared more confluent than those of the negative control (data not shown).
Tukey–Kramer analysis of these results indicated that neither LPS doping nor use
of the probe significantly reduced cell viability (p > 0.05). At both 200 ng/mL and 500
ng/mL, RAW 264.7 cells exhibited viability slightly greater than 100% (p > 0.05), LPS
appears to enhance cell proliferation at these doses, supporting evidence in previous
studies [166], [187] and demonstrating that LPS can stimulate immune cell proliferation.
This result agrees with a phenomenon observed in the inverted microscope: after
incubation with LPS in 24-well plates, these cells often appeared more confluent than
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those of the cell-only control. This effect might be attributed to the greater number of
cells accounting for some of the increase in cumulative H2O2 seen in LPS-doped groups.

Figure 6-11: Effect of LPS or ROS probe operation on viability of RAW 264.7 cells.
96-well plates were seeded with 1 × 104 RAW 264.7 cells, grown to 50% confluency,
and doped with 200 ng/mL or 500 ng/mL LPS, or probed at one of two potential steps:
+0.7 V and +0.3 V. One-way ANOVA (n = 6, p = 0.0029) and Tukey–Kramer post hoc
analysis (n = 6, * p < 0.05, ** p < 0.001) were performed.
The reduction in viability at both voltage steps was just shy of statistical
significance. However, in this assay, the probe was used in 100 µL, rather than 1 mL, of
media (i.e., a 96-well plate, rather than a 24-well plate). It is possible that the closer
confines of the 96-well plate caused additional stress to the cells when the probe was
introduced and operated.
6.5

Conclusions

This work provides a robust demonstration of a Pt MEA probe in an assay of
inflammation. Stable concentrations of extracellular H2O2 released in vitro by activated
macrophages placed under oxidative stress were detected up to 48 h after doping with
LPS. The Pt MEA was used to quickly and quantitatively rapid measure the anti-
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inflammatory effect of Dex on LPS-doped RAW 264.7 cells. This experiment served as
an in vitro model of an assay for inflammation.
Future work with this probe will involve the multiplexing of the probe to allow
for additional ROS/RNS sensing (e.g., the simultaneous detection of H2O2 and nitric
oxide with separate microelectrodes). Further modifications of the Pt MEA will allow
such multiplexed sensing in conjunction with the monitoring of treatment (e.g., the
depletion of therapeutic antioxidants such as ascorbic acid). This additional work could
point toward the creation of a rapid, convenient, minimally invasive, comprehensive,
clinical assay of oxidative stress and inflammation.

CONCLUSIONS AND FUTURE DIRECTIONS
Overall, this multi-pronged research study sought to investigate TBI using two
approaches - through diagnosis and treatment – employing diversified tools in organic
chemistry, neuroscience, animal science and electroanalytical chemistry. The long-term
goal of this study was to mitigate secondary neuroinflammation associated with TBI. The
first approach involved the assessment of a newly discovered BBB-crossing peptide and
its conjugation to an existing anti-inflammatory peptide sequence to study the brainpenetrating ability of the conjugate (FLAP) through neurobehavioral tests and histology
delivered through a non-invasive (IN) route. The second approach was to detect hydrogen
peroxide- the primary redox signal of oxidative stress - using a biosensing platinum
microelectrode array in a minimally invasive assay of inflammation in activated
macrophages. The latter approach could eventually be expanded to create a probe for
detection of chronic levels of neuroinflammation in the brain in TBI.
Before the Fl-L57 and FLAP peptides could be studied in the brain, in vitro
studies were undertaken to verify their uptake in the major cells comprising the BBB
NVU- BMVECs and astrocytes. The NVU, together with the tight junctions, represent a
formidable barrier to the passage of extraneous molecules and thereby prevent their entry
into the brain. Therefore, the successful uptake of the Fl-L57 peptide into these cell types
130
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reflected its potential as a possible BBB vector. When compared to the positive control
peptides A7 and R8, which have both been shown to traverse brain cells in brain uptake
studies, this peptide exhibited significantly higher uptake in all BBB cell types tested,
justifying its utility as a potential BBB vector in further studies. The mechanism of
uptake of the FL-L57 was previously shown to be LRP1 receptor-mediated, and this was
corroborated by their extremely limited uptake into PEA-10 cells. The PEA-10 cell line is
heterozygous for the disruption of the gene for LRP protein, therefore exhibiting low
LRP expression. The lack of uptake of the Fl-L57 peptide into this cell line, in contrast to
its high uptake into astrocytes and BMVECs is possibly indicative of LRP1-mediated
uptake. This in vitro study helped to fill in the gap in the literature concerning the lack of
in vitro uptake in cells comprising the BBB and the possible cytotoxic effects of the
peptide on these cells. Since Fl-L57 uptake was validated by my study and a lack of
cytotoxicity in these cells was confirmed, we concluded that it was a prime new
candidate to expand the rather limited library of BBB-penetrating anti-inflammatory
peptide conjugates.
We then proceeded to conjugate Fl-L57 to an anti-inflammatory peptide to
generate the FLAP peptide for inquiry into the BBB-penetrating ability of this conjugate
with the ultimate intent of dampening neuroinflammation in the brain. Since the original
study had investigated Fl-L57 peptide administration in mouse models through the routes
of in situ brain perfusion through the right common carotid artery and IV injection, we
wanted to try a non-invasive, more facile route, i.e., IN delivery. The IN route has the
distinct advantage of providing more direct access to the brain by directly diffusing
across the nasal epithelial barrier, followed by the olfactory arachnoid membrane.
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In the future, proof of the transcytosis ability of peptides could be elucidated
through the use of transwell plates, particularly in the context of BBB-penetration, using
a co-culture of astrocytes and BMVECs. Expanding on these studies could involve the
comparison of the IN route with other more common routes of peptide administration,
and varying different parameters such as concentration, use of mucoadhesives, absorption
enhancers, and different formulations of the peptide compounds for delivery into the
animal’s body. Moreover, nanoparticle technology is becoming popular for drug delivery
and could be employed to encapsulate the therapeutic peptide. Polysorbate nanoparticles
have been shown to cross the BBB by mimicking LDL, enabling their LDLR-mediated
uptake by brain endothelial cells [188].
During the mFPI, the focal insult to the brain is impacted on the cerebral cortex
and therefore that was initially our target area for peptide localization. Experimental TBI
studies mostly involve the cortical and hippocampal regions, as they are the focal point of
cognitive deficits experienced by many TBI patients [147], [148]. We had hoped that the
concentration of peptide in the cortex would aid in the anti-inflammatory and possibly
neuroprotective properties of the FLAP peptide after the diffuse injury caused by the
head trauma. Our observations through the histology of the brain slices supported the
localization of the peptide in the olfactory bulbs in the brain, but the peptide was missing
from other brain regions. The confirmation of peptide localization was hindered by the
lack of a confocal or 2-photon microscope, either of which could have been used to
visualize peptide localization at submicron levels through optical sectioning.
Nevertheless, the presence of fluorescent aggregates in slices of treated mice brains and
their conspicuous absence from untreated mice brains led to our deduction that peptide
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uptake was present, albeit in olfactory bulbs and not spread throughout the brains. It is
interesting to note that as many as 30% of TBI patients suffer from anosmia, caused by
the axotomy of olfactory receptor neuron (ORN) axons [189]. Only 10% of these patients
show functional improvements after a year [151]. Since few reports address the fact that
diffuse TBI produces damage which can affect OB synaptic reorganization in these
patients [189], more progress needs to be made in ensuring that ORN axons have
successfully regenerated and their function is restored within a reasonable amount of
time. Anti-inflammatory therapy such as the use of minocycline has been found to aid in
the functional recovery of ORN [152]. Since we have demonstrated that the FLAP
peptide localizes in the OB and is also posited to be anti-inflammatory, it could be further
investigated as a potential therapeutic for ORN axonal regeneration.
Owing to the lack of time and resources, we could not investigate the antiinflammatory effects of this peptide through immunohistochemistry/immunofluorescence
staining and Western blot. With the right equipment, the activation levels of GFAP+
astrocyte and IBA1+microglial reactivity after TBI consistent with postinjury
inflammation could be investigated. The lack of a cryotome to ensure micron-level
thickness of the brain slices further hindered our efforts to observe the
progression/improvement of neuronal damage in the brain slices. Additionally, circular
dichroism would be a useful tool to monitor conformational changes in the Trojan horse
peptide upon chemically conjugating it to its peptide (or other molecular) cargo. Any
changes in the secondary structure could provide further insight into the structural
characterization of the peptide conjugate and therefore, its effect on peptide targeting and
activity.
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We did, however, conduct neurobehavioral tests to examine the locomotor skills,
anxiety levels and memory deficits in the mice. Our studies revealed that although the
injured mice showed neurological deficits evidenced by significantly higher mNSS scores
than the sham-injured mice, the OF, NOR and EPM tests did not reveal significant
differences among the treatment groups, possibly because sample sizes were not
sufficient. A longer time frame of testing, such as two weeks, may help illuminate these
differences, if present. This lack of injury-induced effects is also expected for mild or
moderate injury severity levels [153]. Sex- and age-related differences between mice may
also complicate the results of the individual tests. For example, female mice exhibit a
stronger preference for the novel object than males in the NOR test [154]. Different age
groups with sufficient sample numbers could be studied in the future.
In another project, inflammation was investigated in vitro in activated
macrophage cells using an electrochemical hydrogen peroxide-detecting sensor. The goal
was a proof-of-concept study to prove the reliable detection of these species via
chronoamperometry in a robust method of detection. Since H2O2 is chronically elevated
in LPS-induced inflammation, it was a fitting marker of inflammation produced in vitro.
H2O2 was reliably detected at different time points, concentrations, and physiologically
relevant levels of 1-10 µM. The probe also detected an H2O2 – suppressive effect by the
action of anti-inflammatory dexamethasone on LPS-stimulated macrophages,
demonstrating the sensitivity of the probe to changes in peroxide levels. The success of
this probe in this preliminary study in macrophages has beneficial implications in further
studies of inflammation, both in vitro using brain cell types such as microglia, and as an
extracellular assay of inflammation, by possibly sampling brain cerebrospinal fluid to
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assess its levels of ROS in inflamed conditions. This probe also has the potential to be
multiplexed in the future, i.e., to simultaneously sense more than one ROS implicated in
neuroinflammation.
This research study focused on researching aspects of inflammation using
minimally invasive strategies. Projects 1 and 2 demonstrated the ability of the FLAP
conjugate to cross the BBB and study its therapeutic effect on injured mouse brains in a
TBI model, through a non-invasive route of administration. In Project 3, a different
approach was taken to study inflammation. The aim here was to develop a low-cost,
extracellular assay of oxidative stress in TBI using a platinum microelectrode array.
Together, these projects helped advance our understanding of neuroinflammation using
experimental in vitro and in vivo models, with the resourceful use of limited lab
equipment.

This appendix contains the recipes for various reagents that were used in the
course of this research.
Antifade Mounting Media
20mM (final concentration) Tris, pH 8.0 was made and added to 0.5% N-propyl
gallate. The glycerol was warmed then vortexed it and added to the solution making the
final glycerol concentration at 90%. About 6-8 μl of mounting media was used per slice
then the coverslip was placed onto the media, allowing the solution to slowly spread to
the edges. The coverslip was sealed on its sides with clear nail polish. The mounting
media was stored at 4 °C.
4% Formalin
To make 1000 mL 4% formalin, 4g NaH2PO4 and 6.5 g Na2HPO4 were dissolved
in 900 mL DI water and 100 mL of 37% formaldehyde was added. This solution was
stored in a closed glass container at 4 °C.
Cryopreservative
To store slices of mouse brains in the -20 °C freezer, the PBS was first pipetted
out of the wells where the slices were stored, then around 100 µL of the cryopreservative
was added to each well. To make 1000 ml cryoprotectant, 300 mL ethylene glycol, 300
mL Glycerol and 100 mL 0.2M PB were gently stirred together using a magnetic bar. 300
136
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mL distilled water was added and mixed well till the solution became homogeneous. It
was stored at 4 °C.
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